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Background: In the UK almost 7000 people are diagnosed with leukaemia each year, but despite
continuing advances in diagnosis and treatment with new drugs, such as the tyrosine kinase inhibitors,
the majority of these patients will eventually die from their disease. Until quite recently, the only treatment
to offer the possibility of long-term disease-free survival was allogeneic stem cell transplantation. However,
this carries a substantial risk of mortality and is available to only a minority of patients.
Objectives: The aim of the study was to test the hypothesis that molecular and clinical responses, induced
by T lymphocytes (T cells), can be predicted by increases in the number of CD8+ (cluster of differentiation
8-positive) T cells specific for the vaccine-encoded T-cell epitopes. This project also aimed to build on the
established programme of deoxyribonucleic acid (DNA) fusion-gene vaccination delivered by intramuscular
injection, exploiting a unique experience with electroporation, to induce durable immune responses with
the aim of controlling disease by precision attack of the tumour by CD8+ T cells.
Method: A non-randomised, open-label, single-dose-level Phase II clinical trial in two patient groups
[chronic myeloid leukaemia (CML) and acute myeloid leukaemia (AML)] on stable doses of imatinib.
Human leucocyte antigen A2-positive (HLA A2+) patients were vaccinated with two DNA vaccines:
(1) p.DOM–WT1-37 (epitope sequence: VLDFAPPGA); and (2) p.DOM–WT1-126 (epitope sequence:
RMFPNAPYL). The HLA A2-negative patients formed an unvaccinated control group. The sample size for
the HLA A2+ group was originally determined following Simon’s optimal Phase II trial design (Simon R.
Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1–10). This was
changed to A’Hern’s single-stage design during the course of the trial (A’Hern RP. Sample size tables for
single-stage phase II designs. Stat Med 2001;20:859–66), which was endorsed by the trial’s independent
oversight committees.
Results: The study included 12 patients with CML who were vaccinated and nine patients with CML who
were unvaccinated as the control group. Both the vaccines and the electroporation were safe, with no new
or unexpected toxicities. The evaluation adverse events of special interest (heart, bone marrow, renal)
did not reveal safety concerns. Two BCR–ABL (breakpoint cluster region–Abelson murine leukaemia viral
oncogene homolog 1) responses were observed, both of which were defined as a major response, with one in
each group. Two Wilms’ tumour antigen 1 (WT1) molecular responses were observed in the vaccinated group
and one was observed in the control group. At an immunological level, the vaccine performed as expected.
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Conclusions: The study met its primary decision-making target with one major molecular response in
BCR–ABL transcript levels. Overall, the data showed, in this clinical setting, the immunogenicity and safety
of the vaccine.
Limitations: The study did not complete recruitment and there were multiple hurdles that contributed to
this failure. This is disappointing given the robust induction immune responses against WT1 T-cell
responses in 7 out of 10 evaluable patients.
Future work: Evaluation of the p.DOM–WT1 vaccines in AML remains attractive clinically, but it is unlikely
to be feasible at this time. Combination of the DNA vaccine approach with strategies to expand T-cell
responses with immunomodulatory antibodies is in development.
Funding details: This project was funded by the Efficacy and Mechanism Evaluation (EME) programme,
a Medical Research Council (MRC) and National Institute for Health Research (NIHR) partnership,
and Bloodwise.
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Plasmid domain 1 from fragment C of tetanus toxin Used in the vaccine construct as an immune
alert signal.
Wilms’ tumour antigen 1 peptide 37 Peptide from Wilms’ tumour antigen 1 with the amino acid
sequence VLDFAPPGA.
Wilms’ tumour antigen 1 peptide 126 Peptide from Wilms’ tumour antigen 1 with the amino acid
sequence RMFPNAPYL.
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Plain English summary
The Wilms’ tumour antigen 1 (WT1) Immunity via deoxyribonucleic acid (DNA) (WIN) study tested apossible vaccine treatment for patients with chronic myeloid leukaemia (CML) and acute myeloid
leukaemia (AML). The treatment is directed at a molecule called WT1, which helps the survival of
leukaemia cells. The vaccine also contains a small piece of genetic information from the tetanus bacterium,
Clostridium tetani, which, linked to the gene element from WT1, is designed to boost the immune
system to make white blood cells (lymphocytes) that can see and kill leukaemia cells. During the study,
two types of molecules in the blood that are markers for leukaemia were measured: one is WT1 itself,
the other is called BCR–ABL (breakpoint cluster region–Abelson murine leukaemia viral oncogene homolog 1).
The vaccine was administered with a new type of injection called electroporation, designed to make the
vaccine work better.
Twelve patients with CML were vaccinated. It was disappointing that the study was not completed for
various reasons, the main one being slow recruitment. The levels of BCR–ABL were found to be reduced in
one patient, whereas the levels of WT1 were reduced in another patient. The vaccine was well tolerated
and there were no safety concerns. Immune response was evaluable in 10 patients. All responded to the
tetanus component of the vaccine; 70% also made immune responses [CD8+ (cluster of differentiation 8)-
positive T lymphocytes] to WT1. The vaccine had stimulated immune responses as we had hoped.
Evaluation of the p.DOM–WT1 vaccines in AML remains clinically attractive and combination of the DNA
vaccine with booster strategies is in development in the laboratory.
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For chronic myeloid leukaemia (CML), tyrosine kinase inhibition offers significant clinical benefit. Over 85%
of imatinib-treated patients with chronic-phase CML (CML-CP) achieve a complete cytogenetic response
(CCyR), but the majority of patients have a persisting molecular disease, as assessed by quantitative
polymerase chain reaction (qPCR) analysis for the BCR–ABL (breakpoint cluster region–Abelson murine
leukaemia viral oncogene homolog 1) transcripts, and almost all will relapse following imatinib withdrawal.
Functional leukaemia CD34+ (cluster of differentiation 34-positive) progenitor cells have been identified
in such patients in CCyR, suggesting the presence of a reservoir of leukaemia cells resistant to the tyrosine
kinase inhibitor (TKI). Furthermore, the durability of these responses has not yet been established.
The immunological effect of allogeneic stem cell transplantation (alloSCT) and donor lymphocyte infusions
(DLIs) suggests that an approach based on the amplification of the patient’s own immune response to the
disease could add to the responses seen after treatment with TKIs. Based on our own previous data we
argue here that vaccinating against Wilms’ tumour antigen 1 (WT1) using deoxyribonucleic acid (DNA)
vaccination is an attractive choice for delivering this immune attack. WT1 is significantly overexpressed in
all CD34+ subpopulations in CML, encompassing the most primitive haematopoietic stem cell to the most
mature cells, which escape control by imatinib and previous data suggest that active immunotherapy holds
significant promise by the induction of tumour antigen-specific CD8+ (cluster of differentiation 8-positive)
T lymphocytes (T cells) without adding toxicity.
Acute myeloid leukaemia (AML) is a disease of older adults, with a median age of 68 years, and an
incidence of 8–12 per 100,000 of the population. Advances in the understanding of the pathophysiology
of AML have not yet led to major improvements in disease-free and overall survival of adults with this
disease. Only approximately one-third of adults aged between 18 and 60 years who are diagnosed
with AML can be cured; disease-free survival is rare and current therapy is devastating in older adults.
Treatment of AML involves chemotherapy and remission rates are high – up to 85%; however, remissions
are often short lived, and in > 70% of patients the disease progresses and leads to death within 2 years.
In patients with AML, WT1 has been established as a marker for minimal residual disease. Additionally,
based on data from a number of studies. WT1 gene expression has been suggested to carry adverse
prognostic implications in AML. As in CML, peptide vaccination has been tested with some success and
the data support that active immunotherapy other than alloSCT holds significant promise by the induction
of tumour antigen-specific CD8+ T cells without added toxicity.
The purpose of the trial was to build on an established programme of DNA fusion gene vaccination
delivered by intramuscular injection, and exploiting this unique experience with electroporation, to induce
durable immune responses with the aim of controlling disease by precision attack of the tumour by
CD8+ T cells. DNA fusion vaccines were initially developed to treat B-lymphocyte malignancies, which
showed that fusion of the microbial sequence, fragment C from the tetanus toxin (FrC) to the idiotypic
tumour antigen, provided the T-cell help required to induce humoral and CD4+ (cluster of differentiation
4-positive) T-cell responses in preclinical models. An important development has been electroporation,
which has dramatically increased DNA vaccine performance in mice and rhesus macaques and this has
been included in a previous clinical trial in patients with prostate cancer where clear evidence for
amplification of antibody and CD4+ T-cell responses in patients was found. For the induction of CD8+
T-cell responses, the vaccine design was modified by reducing the FrC sequence to a single domain
(p.DOM). This decreased the potential for peptide competition but retained the major histocompatibility
complex class II-restricted peptide p30. An epitope-specific sequence was then inserted at the C-terminus
of FrC to aid processing/presentation.
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The preclinical data predict a response in humans. For patients with relapsed prostate cancer, a p.DOM
epitope design incorporating a peptide sequence from prostate-specific membrane antigen [Gene Therapy
Advisory Committee (GTAC) 089] has induced high levels of epitope-specific interferon gamma, producing
CD8+ T-cell responses in 67% (10/15) of patients. This was the first ever trial to exploit delivery of DNA
by electroporation; this approach was found to be safe and readily accepted by patients. Responses were
robust and persistent over many months to the end of follow-up at 18 months. The clinical effectiveness of
the p.DOM epitope design for the treatment of myeloid malignancies has been explored based on these
clinical results.
The Wilms’ tumour antigen 1 (WT1) gene has emerged as one of the most promising targets for
immunotherapy of haematological malignancies, including CML, AML and myelodysplastic syndromes.
It is also a potential target for the treatment of solid tumours. Despite its ubiquitous expression during
embryogenesis, WT1 expression in normal individuals is limited to renal podocytes, gonadal cells and
a small proportion of CD34+ cells, in which expression is significantly lower (10- to 100-fold). This could
raise a concern about autoimmunity but, reassuringly, the available data document selectivity of attack
against tumour cells, sparing the CD34+ cells and without any evidence of renal or other autoimmune
toxicity in murine models or patients. We and others have tested WT1 peptide vaccines both in preclinical
models and in clinical trials. The latter data document that T-cell responses can be induced in patients
and confirm the presence of an expandable CD8+ T-cell repertoire. Importantly, the ability of peptide
vaccines to induce measurable clinical responses has been documented. However, a key problem with
class I-restricted peptide vaccines is the inability of this approach to provide linked CD4+ T-cell help, crucial
for the maintenance of tumour antigen-specific CD8+ T-cell populations. In the clinic, this is visible
through poor persistence of the detected CD8+ responses.
Preclinically, in a previous study, three domain 1 from fragment C of tetanus toxin (DOM) epitope vaccines
were evaluated, each encoding a different, previously described, WT1-derived, human leucocyte antigen
A2 (HLA A2)-restricted peptide. All were able to induce CD8+ T-cell responses in ‘humanised’, and
presumably tolerised, mice expressing HLA A2 and these killed human WT1-positive (WT1+), HHD+
leukaemia cells ex vivo. A direct comparison with a WT1 peptide vaccine (plus T-cell help and adjuvant)
showed a clear superiority of the DNA fusion vaccine. In parallel, we showed that low numbers of human
WT1 peptide-specific T cells could be expanded in vitro to kill human leucocyte antigen A2-positive
(HLA A2+) (WT1+) leukaemia cells. WT1 peptide 37 (WT1-37) and WT1 peptide 126 (WT1-126) were
selected for current studies. We have already documented clinically the ability of p.DOM epitope vaccines
to induce cytotoxic T cells and anticipate that dual attack against more than one epitope will provide
added clinical benefit. Vaccination with p.DOM–WT1-37 and p.DOM–WT1-126 into different locations will
allow us to avoid antigenic competition. Given the clear effect on the response to the FrC portion of the
vaccine in the prostate trial, electroporation was used as a delivery strategy.
Objectives
The aim of the trial was to bring together substantial preclinical and clinical expertise to exploit the
advantages of DNA fusion vaccines to form the basis for larger, randomised studies.
The objectives were to evaluate:
1. molecular response in patients with CML (i.e. transcript levels of BCR–ABL and WT1) and AML
(i.e. transcript levels of WT1)
2. time to disease progression, 2-year survival rate (patients with AML)
3. correlation of molecular responses with immunological responses.
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This was a non-randomised, open-label, single-dose-level Phase II trial in two patient groups (CML and
AML) based on HLA A2 genotype. HLA A2+ patients were vaccinated with two DNA vaccines:
(1) p.DOM–WT1-37 (epitope sequence: VLDFAPPGA); and (2) p.DOM–WT1-126 (epitope sequence:
RMFPNAPYL). Patients with HLA A2-negative genotype were not vaccinated and formed the control group.
The original trial design followed Simon’s optimal Phase II trial design (Simon R. Optimal two-stage designs
for phase II clinical trials. Control Clin Trials 1989;10:1–10). This was changed to A’Hern’s single-stage
design during the course of the trial (A’Hern RP. Sample size tables for single-stage phase II designs.
Stat Med 2001;20:859–66), which was endorsed by the trial’s independent oversight committees.
Participants
Chronic myeloid leukaemia patients with Philadelphia chromosome-positive CML in chronic phase,
in CCyR but with detectable BCR–ABL transcripts and maintained the CCyR on TKI monotherapy for a
minimum of 24 months, were considered for the trial.
Acute myeloid leukaemia patients with WT1+ AML in complete remission (CR) post chemotherapy or
AML in morphological CR with incomplete blood count recovery, defined as patients who fulfil all of the
criteria for CR except for residual neutropenia (< 1000/µl) or thrombocytopenia (< 100,000/µl).
Eligibility criteria included age ≥ 18 years, a World Health Organization status 0 or 1, a haemoglobin level
of > 100 g/l, a creatinine level of < 1.5× upper limit of normal, liver function tests < 1.5× upper limit of
normal; a lymphocyte count ≥ 1.0 × 1011/l; and normal clotting. These criteria were used to select patients
in the three centres (Southampton, Hammersmith and Exeter) that the trial was conducted in.
Main outcome measures
For the CML treatment group, the primary outcome was molecular response of BCR–ABL and WT1
[major or minor response or complete molecular response (CMR)]. For the AML treatment group, the
primary outcome was time to disease progression and the secondary outcomes were molecular response
of WT1 transcript levels, immune responses to WT1 and DOM, toxicity, CML time to disease progression,
next treatment and survival, AML 2-year survival, WT1 molecular response, overall survival and safety
profile [toxicity according to Common Terminology Criteria for Adverse Events (CTCAE), version 4, and
pain assessment after vaccination]. Immunological responses were key secondary outcomes for both CML
and AML treatment groups.
Trial procedures
Principal investigators identified potential eligible patients from their existing patient population. Patients
who were interested in participating in the trial were provided with the patient information leaflet and
signed the informed consent form prior to enrolment into the trial.
For the intervention group, the DNA vaccine was administered six times every 4 weeks followed by a
further six vaccinations every 3 months to a maximum of 24 months, at the dosing amounts as follows:
l p.DOM–WT1-37: 1mg/dose/vaccine
l p.DOM–WT1-126: 1mg/dose/vaccine.
Patients were followed up as outpatients from the start of treatment to 3 years or withdrawal from
the trial.
Statistical methods
Baseline characteristics and molecular data were summarised by HLA A2 status, together with reasons
for premature withdrawals from treatment and premature withdrawals from the trial.
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The primary outcome of the trial was molecular response of BCR–ABL (major or minor response or CMR),
which was summarised by HLA A2 status. Secondary outcomes included WT1 response (major or minor
response or CMR) and time to disease progression, time to death and time to next treatment, which
were analysed using unadjusted Cox proportional hazards models and by producing Kaplan–Meier
survival curves.
Toxicity was assessed according to CTCAE, version 4.0, and pain assessment information was summarised
in terms of the median and worst pain recorded immediately after and 48 hours post vaccination.
Results
In the 12 patients evaluated, the vaccine and electroporation were safe, with no new or unexpected side
effects. The evaluation of patients for adverse events of special interest (heart, bone marrow and renal)
did not reveal any safety concerns. No significant difference in the frequency of side effects between
the two trial groups was seen. Side effects related to vaccination site reaction were more common in the
HLA A2+ group. In the HLA A2+ cohort, one major molecular BCR–ABL response was seen at week 8.
In the unvaccinated cohort, a molecular response was detected at week 23. Two WT1 molecular responses
were seen in the vaccinated group and one was seen in the unvaccinated group.
At an immunological level, the vaccine performed as expected. Positive responses to the tetanus-derived
component of the vaccine were detected in all (10/10; 100%) evaluable vaccinated patients, providing
confirmation of successful vaccine delivery. Immunological responses to the antigen-specific (WT1)
component of the vaccine were measured using the validated WT1 tetramer assay to measure T cells that
were reactive with the vaccine target, WT1. WT1-specific T cells were detected for 7 out of 10 (70%)
evaluable vaccinated patients. This included responses to WT1-37 in 6 out of 10 (60%) and to WT1-126 in
2 out of 10 (20%) evaluable patients. The immunological analyses for the WT1 Immunity via DNA (WIN)
trial provide evidence to show that the combined p.DOM–WT1 vaccines can stimulate measurable immune
responses against both the DOM and the WT1 components in CML patients in the chronic phase while
being treated with imatinib.
The study met its primary decision-making target with one major molecular response in BCR–ABL transcript
levels and, in parallel, new data emerged illustrating that immune responses detected in the blood appear
to evolve by 6 months post vaccination in most patients. The early onset of the major molecular response
suggests that this response is due to the vaccination. In parallel, a WT1 molecular response was observed.
The study did not complete recruitment and there were multiple hurdles that contributed to this failure.
This is disappointing as the robust induction of FrC responses (10/10 evaluable patients) and WT1 T-cell
responses in 7 out of 10 evaluable patients support that the preclinical data link to immunological
outcomes as predicted. Overall, the data confirmed the immunogenicity and safety of the vaccine.
Recommendations for future research
The observation of a molecular response in 1 out of 12 patients suggests that the rate of clinical benefit in
patients on imatinib in CML in chronic phase is low. Although immune results support effective delivery
of the vaccine and stimulation of the expected immune response, we do not intend to further assess the
vaccine approach in this clinical context. Evaluation of the p.DOM–WT1 vaccine in patients with AML
remains attractive, but it is unlikely to be feasible at this time. A combination of the DNA vaccine approach
with strategies to expand T-cell responses with immunomodulatory antibodies is in development.
SCIENTIFIC SUMMARY
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Trial registration
This trial is registered as EudraCT 2009-017340-14 and ISRCTN62678383.
Funding
This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research
Council (MRC) and National Institute for Health Research (NIHR) partnership, and Bloodwise.
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Importance of the health problem to the NHS
In the UK, 7279 patients were diagnosed with leukaemia in 2005,1 but despite continuing advances
in diagnosis and treatment the majority of these individuals will eventually die from their disease.2
Summary of current evidence
Chronic myeloid leukaemia
Chronic myeloid leukaemia (CML) is a clonal disease of the haematopoietic stem cells (HSCs) in which a
reciprocal translocation, t(9;22)(q34;q11), known as the Philadelphia chromosome, results in a fusion gene,
BCR–ABL (breakpoint cluster region–Abelson murine leukaemia viral oncogene homolog 1), which in turn
expresses an activated tyrosine kinase, and is regarded as the initiating lesion of CML.3,4 Until quite
recently, the only treatment to offer the possibility of long-term disease-free survival was allogeneic stem
cell transplantation (alloSCT), the ‘curative’ effect of which is mediated in large part through the
alloimmune graft-versus-leukaemia (GVL) effect.5 However, alloSCT carries a substantial risk of mortality
and is only available to a minority of patients. Tyrosine kinase inhibitors (TKIs), notably imatinib, have
replaced alloSCT as first-line therapy for CML owing to their lower toxicity and impressive efficacy.
Although > 85% of imatinib-treated patients with chronic-phase CML (CML-CP) achieve a complete
cytogenetic response (CCyR), the majority of patients have persisting molecular disease, as assessed by
quantitative polymerase chain reaction (qPCR) for BCR–ABL transcripts, and almost all will relapse following
imatinib withdrawal.6,7 Functional leukaemia CD34+ (cluster of differentiation 34-positive) progenitor cells
have been identified in such patients within CCyR, suggesting the presence of a reservoir of leukaemia
cells resistant to TKIs.8 Furthermore, the durability of these responses has not yet been established.
In contrast, long-term survivors of alloSCT very rarely have any detectable molecular disease, indicating that
all leukaemia cells must be susceptible to immune destruction (GVL effect). Therefore, novel strategies to
eradicate quiescent CML stem cells are required, especially because these cells provide a reservoir for
disease relapse.
The immunological effect of alloSCT and donor lymphocyte infusions (DLIs) suggests that an approach
based on the amplification of the patient’s own immune response to the disease could add to the
responses seen after treatment with the TKI.
Based on our own data we argue here that vaccinating against the Wilms’ tumour antigen 1 (WT1),
using deoxyribonucleic acid (DNA) vaccination, is an attractive choice for delivering this immune attack.9,10
The validity of WT1, as a target for immunotherapy in CML, was recently shown in work published
by Yong et al. [in John Barrett’s group at the National Institutes of Health (USA)].11 This group studied
the expression of leukaemia-associated antigens, including WT1, within the CD34+ primitive stem cell
and committed progenitor cell pools in CML patients. WT1 is significantly overexpressed in all CD34+
subpopulations in CML encompassing the most primitive HSCs to the most mature cells,11 which escape
control by imatinib. Taken in the context of these clinical data and that from other groups, which show
that even suboptimal vaccination with peptide can have clinical effects,11,12 these data strongly suggest that
active immunotherapy other than allotransplantation holds significant promise by the induction of tumour
antigen-specific CD8+ (cluster of differentiation 8-positive) T lymphocytes (T cells) without adding toxicity.
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Clearly it is critical to choose the best clinical setting in which to vaccinate, as previous data have shown
that the effect of TKIs as a drug class on the immune system is variable,13 and can be either suppressive or
stimulatory. For imatinib specifically, in vivo data show that it can be immunostimulatory, supporting our
proposed trial, both in murine14,15 as well as human16–18 studies. Furthermore, Wang et al.14 demonstrated that
in vivo treatment with imatinib not only prevented the induction of tolerance, while preserving responsiveness
to a subsequent immunisation, but, critically, enhanced vaccine efficacy. In patients, low-frequency CD8+
T-cell responses to four leukaemia-associated antigens (ABL kinase, proteinase 3, telomerase and WT1) were
detected in CML patients on imatinib and show the immune system’s ability to respond to leukaemia-associated
antigens in the presence of imatinib.19 It is therefore unsurprising that two vaccine studies using BCR–ABL
peptides in patients with CML treated with imatinib clearly demonstrated the successful induction of CD8+
and CD4+ (cluster of differentiation 4-positive) T cells against the vaccine, even with a suboptimal peptide
vaccine approach.20,21 Bocchia et al.20 found that antileukaemia T-cell responses could be stimulated after
vaccination in 9 out of 14 patients. In the EPIC trial, T-cell responses to CD4+ T-cell responses against the
vaccine were seen in all patients and 14 of 19 patients developed T-cell responses to BCR–ABL peptides.21
Prospective analysis of immune responses to vaccination against influenza A (H1N1, 2009 strain) and
Streptococcus pneumoniae (Klein 1884) Chester 1901 in 50 CML-CP patients treated with imatinib (Glivec®,
Novartis Pharmaceuticals UK Ltd), dasatinib (Sprycel®, Bristol-Myers Squibb) or nilotinib (Tasigna®, Novartis
Pharmaceuticals UK Ltd) and 15 healthy controls was recently performed.22 Significant CD8+ and CD4+ T-cell
responses against flu were induced in patients with CML-CP on TKIs following vaccination and there was no
significant difference in the vaccine-induced T-cell response between CML-CP patients on TKIs and healthy
controls (manuscript in preparation). These data strongly support that vaccination of patients on stable doses
of imatinib will induce immune responses.
Acute myeloid leukaemia
Acute myeloid leukaemia (AML) is a disease of older adults with a median age of 68 years23 and an
incidence of 8–12 per 100,000 population. Advances in the understanding of the pathophysiology of AML
have not yet led to major improvements in disease-free and overall survival of adults with this disease.
Only about one-third of those aged between 18 and 60 years who are diagnosed with AML can be cured;
disease-free survival is rare and current therapy is devastating in older adults. Treatment of AML involves
chemotherapy with high remission rates in up to 85% of patients; however, remissions are often short
lived and > 70% of patients will progress and die from their disease within 2 years (see Figure 1).24
Treatment also causes significant morbidity and mortality. AlloSCT from a compatible donor carries a
20–75% chance of long-term disease-free survival depending on whether the transplant is performed in
remission or with residual disease. Death from relapse is the most common cause of treatment failure
following transplant. At this point, a minority of patients respond to chemotherapy and DLIs, but remission
rates are around 15% with only a fraction being durable.17,18 There is, therefore, a need to devise better
treatments for AML.
In AML, WT1 has been established as a marker for minimal residual disease (MRD).25 Additionally, WT1
gene expression has been suggested to carry adverse prognostic implications in AML based on data from
a number of studies.26,27 A recent trial by the European LeukemiaNet defined and standardised a WT1
real-time qPCR assay as a marker for MRD monitoring and risk stratification in AML.28 We intend to exploit
this for the proposed trial of WT1 vaccination. As in CML, peptide vaccination has been tested with some
success12,29–33 and the data support that active immunotherapy other than allotransplantation holds
significant promise by the induction of tumour antigen-specific CD8+ T cells without added toxicity.
The purpose of the trial was to build on an established programme of DNA fusion gene vaccination
delivered by intramuscular injection and exploiting this unique experience with electroporation, to induce
durable immune responses with the aim of controlling the disease by precision attack of the tumour by
CD8+ T cells. The aim of the trial was to evaluate an identical vaccine strategy in two parallel settings with
the purpose of identifying the most promising context for eventual Phase III testing. The hypothesis was
that molecular and clinical responses, induced by T cells can be predicted by increases in the number
of CD8+ T cells, specific for the vaccine-encoded T-cell epitopes.
BACKGROUND
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Trialling two patient groups will maximise the knowledge gained from this vaccine trial. Patients with CML
will allow a direct and objective assessment of the antileukaemia effect of vaccination at the molecular
level by BCR–ABL and WT1 monitoring. Patients with AML offer a difficult challenge to haematologists.
The advantage of including this patient group is twofold: (1) the antileukaemia effect of vaccination can be
assessed objectively by measuring WT1 gene expression levels; and (2), more importantly, data can be
collected on the highly clinically relevant question of whether or not vaccination will prevent relapse in this
patient group.
Selection of patients for vaccine therapy
Novel therapies are often first introduced in patient groups who have failed all conventional treatment
options and have far advanced or metastatic disease. This strategy is inappropriate for vaccine treatments,
which depend upon an intact well-functioning immune system, known to be severely impaired in
advanced cancers. The cohort to be studied here has therefore been chosen to reflect this conclusion.
Immunotherapy in haematological malignancies targeting Wilms’ tumour
antigen 1
DNA fusion vaccines were initially developed to treat B-cell malignancies,34 which showed that fusion of
the microbial sequence, fragment C from the tetanus toxin (FrC) to idiotypic tumour antigen provided the
T-cell help required to induce humoral35 and CD4+ T-cell responses in preclinical models.36 Early clinical
testing was undertaken in a Phase I/II dose escalation trial [LIFTT trial; Gene Therapy Advisory Committee
(GTAC) 029A], with individual idiotypic DNA fusion vaccines to treat patients with follicular lymphoma.
The vaccine was safe and 14 out of 18 patients showed an antibody and/or CD4+ T-cell responses against
the FrC portion of the fusion gene. Encouragingly, 6 out of 16 patients showed responses to the
tumour-specific idiotypic antigen (manuscript in preparation). There was no evidence of a dose response
for doses ranging from 500 µg/dose to 2500 µg/dose.9 Overall, however, the levels of response were
relatively low and improvements were sought.
An important development has been electroporation, which has been shown to dramatically increase
DNA vaccine performance in mice37 and rhesus macaques,38 and this method of delivery was used in our
clinical trial in patients with prostate cancer. We found clear evidence for amplification of antibody and
CD4+ T-cell responses in patients.39 For induction of CD8+ T-cell responses, the vaccine design was
modified by reducing the FrC sequence to a single domain (p.DOM; plasmid domain 1 from FrC).
This decreased the potential for peptide competition but retained the major histocompatibility complex
class II-restricted peptide p30.39 An epitope-specific sequence was then inserted at the C-terminus of FrC
to aid processing/presentation. In multiple models, this p.DOM epitope design (Figure 1a) was able to
induce high levels of epitope-specific CD8+ T cells.9
Importantly, provision of high levels of T-cell help enables induction of immune responses in
tolerant settings.9,39
The preclinical data appear to predict response in humans.10 For patients with relapsed prostate cancer,
a p.DOM epitope design incorporating a peptide sequence from the prostate-specific membrane antigen
(PSMA; GTAC 089) has induced high levels of epitope-specific interferon gamma (IFN-γ), producing
CD8+ T-cell responses in 67% (10/15) of patients.40 Data from the 10 patients in the group receiving the
lowest dose levels of DNA and DNA/electroporation are shown in Figure 1b. This was the first ever trial
to exploit delivery of DNA by electroporation and it was found this approach was safe and readily accepted
by patients.10 Responses were robust and persistent over many months to the end of follow-up in the trial
at 18 months (Figure 1b).
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Figure 2 illustrates the CD8+ T-cell analyses in more detail. In Figure 2a and 2b two non-responders are
shown, one of whom (Figure 2b) had pre-existing levels of PSMA peptide 27-specific T cells at baseline.
It is interesting to note that these cells appear to leave the circulation post vaccination and become visible
again after the first booster injection at 6 months. Further data are required to allow interpretation of
this observation. In Figure 2c and 2d, two of the six responders at dose level 1 are shown. The patient in
Figure 2c was treated with DNA alone followed by DNA delivered by electroporation, whereas the patient
in Figure 2d was treated with DNA/electroporation on five occasions.
The effectiveness of the p.DOM epitope design for the treatment of myeloid malignancies has been
explored based on these clinical results. WT1 has emerged as one of the most promising targets for
immunotherapy of haematological malignancies including CML, AML and myelodysplastic syndromes.29,41–43
It is also a potential target for the treatment of solid tumours.43–46 Despite its ubiquitous expression during
embryogenesis, WT1 expression in normal individuals is limited to renal podocytes, gonadal cells and a small
proportion of CD34+ cells,47–50 where expression is significantly lower (10- to 100-fold).47 This could raise a
concern about autoimmunity, but, reassuringly, the available data document selectivity of attack against
tumour cells, sparing the CD34+ cells51,52 and without any evidence of renal or other autoimmune toxicity in
murine models53–55 or patients.29,41–43
The WT1 peptide vaccines have been tested both in preclinical models51,52,56 and in clinical trials.12,41–43 The
data from clinical trials document that T-cell responses can be induced in patients and confirm the presence
of an expandable CD8+ T-cell repertoire. Importantly, the ability of peptide vaccines to induce measurable





























































Non-responders, n = 4
Responders, n = 6
FIGURE 1 Vaccination of patients with the p.DOM epitope vaccine. (a) The p.DOM epitope vaccine consists of a
DNA plasmid backbone incorporating cytosine–phosphate–guanine sites. The first domain of the tetanus toxin
(DOM; TT865–1120) provides T-cell help when linked to a tumour-associated nucleotide sequence encoding
the human leucocyte antigen class I binding epitope of interest. This format allows the appropriate processing
and presentation of the peptide. (b) Spots per million peripheral blood mononuclear cell producing IFN-γ in
human leucocyte antigen A2-positive patients treated with three monthly doses of DNA (p.DOM.PSMA27).
The figure shows data from the first dose cohort, analysed in a cultured.
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inability of this approach to provide linked CD4+ T-cell help, which is crucial for the maintenance of tumour
antigen-specific CD8+ T-cell populations. In the clinic, this is visible in poor persistence of the detected
CD8+ T-cell responses. In contrast, it was that the p.DOM epitope fusion vaccines appeared to be able to
deliver CD8+ T-cell responses, which show long-term persistence (see Figures 1b and 2c and 2d).
Recently, three domain 1 from fragment C of tetanus toxin (DOM) epitope vaccines were evaluated, each
encoding a different, previously described, WT1-derived, human leucocyte antigen A2 (HLA A2)-restricted
peptide.56 All were able to induce CD8+ T-cell responses in ‘humanised’, and presumably tolerised, mice
expressing HLA A2 and these killed human WT1-positive (WT1+), HHD+ leukaemia cells ex vivo. A direct
comparison with a WT1 peptide vaccine (plus T-cell help and adjuvant) showed a clear superiority of the
DNA fusion vaccine.56 In parallel, we showed that low numbers of human WT1 peptide-specific T cells
could be expanded in vitro to kill WT1+ HLA A2+ leukaemia cells. The WT1 peptide 37 (WT1-37)
and WT1 peptide 126 (WT1-126) peptides were selected for current studies. We have already documented
clinically the ability of p.DOM epitope vaccines to induce cytotoxic T lymphocytes (CTLs) and anticipate
that dual attack against more than one epitope will provide added clinical benefit.9,10 Vaccination with
p.DOM–WT1-37 and p.DOM–WT1-126 into different locations will allow us to avoid antigenic
competition. Given the clear effect on the response to the FrC portion of the vaccine in the prostate trial,




































































































































































































































FIGURE 2 The CD8+ T-cell responses to DNA vaccination analysed over time by enzyme-linked immunospot.
(a) and (b) show data on two out of four non-responders, of which the patient in (b) shows a low-level CD8+ T-cell
response to the PSMA peptide 27 at baseline. As there is no significant increase in levels of PMBCs producing IFN-γ
above the baseline, this patient has been classified as a non-responder; (c) and (d) show examples of patients that
have significantly increased levels of PMBCs producing IFN-γ compared with baseline levels and to the human
immunodeficiency virus-negative control. (n= 6 in the first dose cohort.) HIV, human immunodeficiency virus;
PBMC, peripheral blood mononuclear cell.
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Recently, three DOM epitope vaccines were developed, each encoding a different, previously described,WT1-derived, HLA A2-restricted peptide.56 All vaccines were able to induce CD8+ T-cell responses in
‘humanised’, and presumably tolerised, mice expressing HLA A2, and these T cells were capable of
killing human WT1+ HHD+ leukaemia cells ex vivo. A direct comparison with a WT1 peptide vaccine
(plus T-cell help and adjuvant) showed a clear superiority of the DNA fusion vaccine.56 In parallel, we
showed that low numbers of human WT1 peptide-specific T cells could be expanded in vitro to kill HLA
A2+ WT1+ leukaemia cells.56 Peptides WT1-37 (amino acid sequence: VLDFAPPGA) and WT1-126
(amino acid sequence: RMFPNAPYL) were selected for current studies.
The ability of p.DOM epitope vaccines to induce CTLs has been documented clinically and we anticipate
that dual attack against more than one epitope will provide added clinical benefit. Vaccination with
p.DOM–WT1-37 and p.DOM–WT1-126 into different locations will allow us to avoid antigenic
competition. Given the clear effect on the response to the FrC portion of the vaccine in the prostate trial,
electroporation was chosen as the vaccine delivery strategy.10
The aim of this trial was to bring together substantial preclinical and clinical expertise to exploit the
advantages of DNA fusion vaccines to form the basis for larger, randomised studies.
The objectives were to evaluate the:
1. molecular response in patients with CML (i.e. transcript levels of BCR–ABL and WT1) and AML
(i.e. transcript level of WT1)
2. time to disease progression, 2-year survival rate (patients with AML)
3. correlation of molecular responses with immunological responses.
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Chapter 3 Trial design and methods
Trial design
This was a non-randomised, open-label, single-dose-level Phase II trial in two patient groups (CML and AML)
based on HLA A2 genotype. HLA A2+ patients were vaccinated with two DNA vaccines: (1) p.DOM–WT1-37
(epitope sequence: VLDFAPPGA); and (2) p.DOM–WT1-126 (epitope sequence: RMFPNAPYL). Patients with
HLA A2-negative (HLA A2–) genotype were not vaccinated and formed the control group. Patients were
tested for the presence of the human immunodeficiency virus (HIV), hepatitis B, hepatitis C and syphilis to
protect the laboratory personnel, and because these infections may have a significant impact on the
immunocompetence of the patient.
Significant change to trial design
The original trial design used Simon’s optimal Phase II trial design.57,58 This allowed us to undertake a
‘start/stop’ evaluation once 12 patients had been enrolled into each vaccination group of the study and
had been evaluated to 6 months (molecular monitoring). An interim analysis of these CML patients’
molecular data (BCR–ABL and WT1) was to be carried out including up to 6 months of data. If a molecular
response (change in transcript level of BCR–ABL or WT1) was observed the CML arm may recruit an
additional 25 participants. It was designed that the AML arm would also be opened to recruitment at
this point.
It became evident early on in the trial that recruitment of the CML patients was significantly behind target.
At the same time, new data emerged which illustrated that immune responses detected in the blood
appear to evolve by 6 months post vaccination in most patients.56 These data were not available when the
WT1 Immunity via DNA (WIN) trial protocol was developed. Clinical responses (reduction in BCR–ABL
transcript levels) are therefore also expected to happen late which would necessitate a halt in recruitment
to ‘observe’ outcomes in the first stage prior to initiating the second stage.
This new information manifested to protocol amendment six. The following changes were included in this
amendment to increase the available eligible CML patient population and help speed up recruitment:
l The AML arm was to be opened, independent of the CML result, as a result of the new data that had
emerged illustrating that immune responses detected in the blood appear to evolve by 6 months in
most patients.
l Patients on any TKI became eligible (rather than just those on imatinib).
l The trial design was changed from Simon’s two-stage design58 to A’Hern’s single-stage design.59
l Amendment to the sample size for the trial to observe a minimum of 4 out of 32 CML patients who
are molecular responders in order to provide evidence that the vaccine warrants further investigation.
This is an increase proportionally from 10.8% (4/37) to 12.5% (4/32) and allowed all patients to
receive all 12 vaccinations rather than only receive an additional six based on response being observed.
Early closure of the trial
The CML arm of the trial was terminated early by the funders because of poor recruitment. This meant
that recruitment of the AML arm could not be implemented until an assessment was done to secure
funding to continue with this arm of the trial. The outcome of this assessment was to close the trial.
The Research Ethics Committee and the Medicines and Healthcare products Regulatory Agency (MHRA)
were notified on the 3 April 2014.
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The study met its primary decision-making target with one major molecular response in BCR–ABL transcript
levels and, in parallel, new data emerged which illustrated that immune responses detected in the blood
appear to evolve by 6 months post vaccination in most patients.56 The early onset of the major molecular
response suggests that vaccination has achieved this molecular event. In parallel, a WT1 molecular response
was observed.
A significant amount of time and effort was utilised in an attempt to overcome multiple hurdles that
prevented successful recruitment, but despite this the study did not complete recruitment. The failure to
achieve the recruitment target was exclusively driven by the lack of recruitment of CML patients.
Some of the major hurdles which contributed to the failure of the studies are as follows:
l The agreement and enthusiasm of the principal investigator (PI) for the centre at Hammersmith to
participate in the study was not matched by a main member of the team to recruit to the study, leading
to a lack of recruitment from the centre where the largest number of CML patients was expected.
l At the feasibility stage, the expert haemato-oncologist (PI) at Hammersmith assessed the cohort size
of eligible patients to be 500 patients with CML who would fulfil the entry criteria for the study.
This meant that 70% of the recruitment would come from the cohort size at this centre. Unfortunately,
neither the cohort size nor recruitment materialised and this was key to the success of the study.
l Apparent lack of clinical efficacy by the vaccination and, therefore, less interest in the study.
l The unexpected loss of the PI to a US centre, leaving the study unsupervised in the key centre.
The following key reasons contributed to the failure to achieve the recruitment target:
l Extensive attempts were made by the chief investigator via the National Institute for Health Research
(NIHR) clinical studies group and by visiting national key centres, which mange CML, to recruit new
centres to the study. Although there was significant academic interest for this study, it competed
directly with an ongoing study in CML, precluding their participation.
l As highlighted above, the NIHR Efficacy and Mechanism Evaluation (EME) programme did not support
recruitment of AML patients. Therefore, recruitment of this study arm was stopped and no patients were
vaccinated; it was deemed unethical to recruit one or two patients to the AML arm and then stop the trial.
This was disappointing as the robust induction of FrC responses (10/10 evaluable patients) and WT1
T-cell responses in 7 out of 10 evaluable patients support that the preclinical data link to immunological
outcomes as predicted. Overall, the data confirmed the immunogenicity and safety of the vaccine.
Ethical approval and research governance
Ethical approval for the trial was given by the GTAC, National Research Ethics Service National Patient
Safety Agency (24 September 2010, reference number GTAC 173). The trial was registered with the
International Standard Randomised Controlled Trial Register (ISRCTN) under the reference number
ISRCTN 62678383.
Changes to original protocol
A summary of the changes to the original protocol is given in Table 1.
Trial setting and sample
Three hospitals (Southampton General Hospital, University Hospital Southampton NHS Foundation Trust;
Hammersmith Hospital, Imperial College Healthcare NHS Trust; and Royal Devon and Exeter Hospital,
The Royal Devon and Exeter NHS Foundation Trust) were selected to undertake the trial based on their
interest, clinical experience and the number of patients with AML and CML patients who may be suitable
to participate in the trial. It was anticipated that the Hammersmith Hospital would contribute the majority
TRIAL DESIGN AND METHODS
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TABLE 1 Summary of changes to the original protocol
Change in protocol REC/MHRA approvals
Amendment 1
Protocol version 1 (20 June 2010): MHRA non-acceptance 28 September 2010
Protocol version 1 (7 July 2010): conditional approval only
Protocol version 2 (9 September 2010): conditions addressed and protocol approved
Addition of electrocardiography at baseline; logistical changes made for supply and return of
IMP; and clarification on monitoring
Amendment 2
Protocol version 3 (7 October 2010): used to open sites 1 November 2010
Update in the IMPD included in the protocol
Amendment 3
Protocol version 4 (29 June 2011): clarifications 12 August 2011
Clarification of patient pathway throughout the trial from consent; clarification on the
schedule of observations and procedure for HLA A2– participants; clarification on inclusion
criteria for AML patients with regards to WT1 status; clarification determination of bone
status for trial inclusion; clarification on resupply of IMP to sites; clarification of local and
central laboratory responsibilities and shipment of samples; amendment of pain assessment
case report form to remove patient identifiers; and addition of delayed-type hypersensitivity
reaction to be carried out wherever feasible
Amendment 4
Protocol version 5 (18 October 2011): eligibility broadened 16 January 2012
Eligibility criteria amended to allow patients with a 6-month history of lymphocyte counts of
just below 1 to be included in the trial
Amendment 5
Protocol version 5 (18 October 2011): changes to the IMPD; no changes to the protocol 17 May 2012
Stability data for p.DOM–WT1 DNA vaccines to support the proposed expiry date extension
plan at the predetermined 18-month time point
Amendment 6
Protocol version 6 (31 July 2012): eligibility broadened and trial design changed 8 November 2012
Eligibility criteria widened to include all TKIs to increase recruitment; change in trial design
from a two-stage design to a single-stage design; sample size adjusted to 32 CML patients
and 37 AML patients; all HLA A2+ patients to receive all 12 vaccinations instead of receiving
the second six only if a response is observed
Amendment 8
Protocol version 6 (31 July 2012): no change to the protocol; temporary halt to the trial 11 April 2013
CML arm of the trial stopped and temporary halt on trial for AML arm
Amendment 10
Protocol version 7 (1 October 2013): reduction in follow-up visits 7 November 2013
Patients last follow-up 12 months post final vaccination. The enzyme-linked immunospot
(ELISPOT) assay removed from end-point analysis (replaced by tetramer staining).
The 36-month follow-up visit removed
End of trial notification 3 April 2014
IMP, investigational medicinal product; IMPD, investigational medicinal product dossier; REC, Research Ethics Committee.
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of the CML patients based on the cohort of about 500 patients treated with imatinib with stable disease.
Smaller numbers were expected from Exeter and Southampton.
Inclusion criteria
Chronic lymphocytic leukaemia patients
Those CML patients:
l who have Philadelphia chromosome-positive CML in chronic phase
l who are in CCyR but with detectable BCR–ABL transcripts and maintain the CCyR on TKI monotherapy
for a minimum of 24 months.
Acute myeloid leukaemia patients
Those AML patients who have either:
l WT1-positive AML in complete remission (CR) post chemotherapy
l or AML in morphological CR with incomplete blood count recovery defined as patients who fulfil all of
the criteria for CR except for residual neutropenia (< 1000/µl) or thrombocytopenia (< 100,000/µl).
All patients
l Aged ≥ 18 years.
l Written informed consent.
l World Health Organization (WHO) performance status of 0 or 1.
l For vaccination groups: HLA A2+ in at least one allele.
l For control groups: HLA A2– in both alleles.
l Renal function and liver function (creatinine < 1.5 × upper limit of normal, liver function tests
< 1.5 × upper limit of normal); lymphocyte count ≥ 1.0 × 109/l (if the lymphocyte count was
< 1.0 × 109/l at the time of entry into the trial but had been > 1.0 × 109/l in the last 6 months and
had also not declined rapidly in the days and weeks preceding entry, then the patient was eligible);
and normal clotting.
l Haemoglobin level of > 100 g/l.
l Adequate venous access for repeated blood sampling according to the protocol schedule.
l If sexually active and possibly fertile, patients must have agreed to use appropriate contraceptive
methods during the trial and for 6 months afterwards.
Eligibility criteria were widened to include all TKIs (previously imatinib only) to increase recruitment
(amendment 6, 8 November 2012; see Table 1).
Exclusion criteria
Chronic lymphocytic leukaemia patients
l Chronic lymphocytic leukaemia in accelerated phase or blast crisis or having achieved complete
molecular response (CMR) at any point during TKI therapy.
l A TKI change or dose modification in the previous year, therapy interruption for > 15 days in the
6 months prior to enrolment.
l Prior interferon alpha therapy.
l Hypocellular bone marrow (< 20%; indicated by blood counts and most recent bone marrow,
where available).
l A CMR.
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Acute myeloid leukaemia patients
l Acute myeloid leukaemia in haematological relapse or eligible for alloSCT.
l Hypocellular bone marrow (< 20%).
l Acute myeloid leukaemia patients with the ‘good-risk’ abnormalities comprising by the core-binding
factor leukaemias [i.e. AML with the translocation (8;21) and inversion of chromosome 16, and acute
promyelocytic leukaemia with the translocation (15;17)].
All patients
l Systemic steroids or other drugs with a likely effect on immune competence were forbidden during
the trial. The predictable need of their use precluded the patient from trial entry. Inhaled steroids
were allowed.
l Major surgery in the preceding 3–4 weeks from which the patient had not yet recovered.
l Patients who were of high medical risk because of non-malignant systemic disease, as well as those
with active uncontrolled infection.
l Patients with any other condition which, in the investigator’s opinion, would not make the patient a
good candidate for the clinical trial, such as concurrent congestive heart failure or prior history of
New York Heart Association class III or IV cardiac disease.
l Current malignancies at other sites, with the exception of adequately treated basal or squamous cell
carcinoma of the skin. Cancer survivors, who had undergone potentially curative therapy for a prior
malignancy, had no evidence of that disease for 5 years and were deemed at low risk of recurrence,
were eligible for the trial.
l Patients who are serologically positive for, or are known to suffer from, hepatitis B or C, syphilis or HIV.
Counselling was offered to all patients prior to testing.
Trial interventions
The trial was an open-label trial with two groups for both the CML and AML arms:
l intervention group: all eligible and consenting patients who were HLA A2+
l control group: all eligible and consenting patients who were HLA A2–.
For the intervention group, the DNA vaccine was administered six times every 4 weeks followed by a
further six vaccinations every 3 months to maximum of 24 months at the following dosing amounts:
l p.DOM–WT1-37: 1mg/dose/vaccine
l p.DOM–WT1-126: 1mg/dose/vaccine.
The original protocol planned that patients would be given vaccines six times, at 4-weekly intervals, and
only if a response was observed would they go on to receive the remaining six vaccinations at 3-monthly
intervals up to a maximum of 24 months. New data emerged which illustrated that immune responses
detected in the blood appear to evolve by 6 months in most patients;58 therefore, the protocol was
amended to allow all HLA A2+ patients to receive all 12 vaccinations instead of receiving the second six
only if a response was observed.
The vaccine was manufactured at the MHRA-approved Clinical Biotechnology Centre at the Bristol Institute
for Transfusion Science (Bristol, UK) in accordance with good manufacturing practice.
The amount of DNA used was 1mg/dose for p.DOM–WT1-37 and 1mg/dose for p.DOM–WT1-126
(at a final concentration of 1mg/0.8 ml). The vaccine was supplied in standard phosphate-buffered saline.
The DNA for injection was divided into aliquots for storage at –70 °C in sterile glass vials, and aliquots for
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sterility and stability testing. The testing was based on the guidelines for injectables described in the
European Pharmacopoeia (http://edpm.eu). The most likely contaminant is protein, which was expected
to be < 1%. The material was confirmed as pyrogen free by using a Limulus test (BioWhittaker UK Ltd,
Wokingham, UK). After delivery to the hospital pharmacy, the vaccine was stored at –70 °C.
The vaccine was thawed for approximately 5 minutes so that it was at room temperature before
administration. The vaccines were injected by deep intramuscular injection into separate sites followed
by electroporation.
The electroporation device (Elgen1000, Inovio Biomedical corporation, San Diego, CA, USA) was a system
specifically designed for the delivery of electrical pulses to selected tissues, including muscle, to facilitate
the intracellular uptake of plasmid DNA. The device locally applies controlled, short-duration electric pulses
to target tissues to create an electric field that temporarily increases cellular membrane permeability
allowing the plasmid DNA to enter the cells.
Operators underwent formal training before being considered competent in the use of the device.
Training was provided by Inovio Pharmaceuticals, Inc. (San Diego, CA, USA).
Vaccination schedule
The DNA vaccine was administered 12 times. Patients received the vaccine at 4-weekly intervals into
separate sites for the first 6 months, followed by vaccinations every 3 months up to a maximum
of 24 months. Vaccines were injected intramuscularly and followed by intramuscular electroporation.
Pain assessments were conducted immediately after vaccination and at 48 hours post vaccination.
The first HLA A2+ patient recruited at each site was evaluated 48 hours after administration of the first
vaccination, before additional doses were given or before additional patients were vaccinated at that site.
Trial procedures
Recruitment and informed consent
The PIs identified potential eligible patients from their existing patient population either during routine
consultation or from a database search. Patients identified from their database were approached for the
trial at their next clinic appointment. Patients who were interested in participating in the trial were
provided with the patient information leaflet and signed the informed consent form prior to enrolment
into the trial.
Registration
After written informed consent was obtained from the patient and before screening commenced,
sites registered the patient with the Southampton Clinical Trials Unit (SCTU) to obtain the unique patient
identification number. The patient’s eligibility was checked during the registration process to ensure that
only patients fulfilling the eligibility criteria were registered. Subsequently, the patient identification number
was assigned.
Data collection and management
Sites entered trial-specific data, as specified in the protocol, onto paper case report forms (pCRFs).
Completed pCRFs were sent to the SCTU, which was responsible for the data management of the trial.
Data were transcribed from pCRFs into an InForm database (InForm version 5.0, ORACLE) at the SCTU.
A range of data validation checks were carried out within both InForm and SAS version 9.3 (SAS Institute Inc.,
Cary, NC, USA) or above to minimise incorrect or missing data.
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Molecular samples were sent to Haematology department at Hammersmith Hospital (a clinical
pathology-accredited MRD laboratory) for molecular monitoring (qPCR for BCR–ABL/WT1 in CML and WT1
in AML). This is an accepted and routine test for monitoring of this disease. Results from the analysed
samples were regularly sent back to SCTU for statistical analysis.
Immunological analyses for vaccine responses, including leukapheresis samples and bone marrow samples,
were processed and frozen locally according to an agreed standard operating procedure and stored in
liquid nitrogen. Samples were transported to the Cancer Sciences Division (Southampton General Hospital,
Southampton, UK) in dry ice and using a temperature logger once a sufficient number or samples had
been collected locally (Hammersmith Hospital, Exeter, UK).
Source data verification was undertaken during site monitoring visits, in accordance with the SCTU’s trial
monitoring plan. Sites were visited at least once during the trial. At least one monitoring visit was
undertaken for each participating site. A total of three planned monitoring visits and one triggered
monitoring visit were carried out.
Baseline
The baseline investigations/evaluations that were performed on patients before vaccination included bone
marrow aspiration, electrocardiogram (ECG), chest X-ray, HLA A2 status verification, vital signs, WHO
performance status, urinalysis, full blood counts (FBCs), blood clotting test, biochemistry (levels of sodium,
potassium, calcium, phosphorus, urea and creatinine; total protein, albumin, bilirubin, alkaline phosphate,
alanine transaminase, aspartate transaminase mad gamma-glutamyl transferase levels), the creatine kinase
(CK) test (for HLA A2+ patients), tests for the presence of syphilis, hepatitis B, hepatitis C and HIV, qPCR
(for BCR–ABL and WT1 in CML patients and for WT1 in AML patients), leukapheresis for immunological
studies (HLA A2+ patients only), autoimmune profiling and checks for concomitant diseases/treatments.
Follow-up
Patients were followed up as outpatients from the start of treatment at the time points outlined below.
Each visit was done from baseline ± 14 days.
l Visit 1: week 0, within 7 days of baseline.
l Visit 2: week 2.
l Visit 3: week 4.
l Visit 4: week 8.
l Visit 5: week 10.
l Visit 6: week 12.
l Visit 7: week 16.
l Visit 8: week 20.
l Visit 9: week 22.
l Visit 10: week 24.
l Visit 11: week 32.
l Visit 12: week 34.
l From visit 13 onwards, patients were seen at the following time points from baseline ± 14 days:
months 11, 14, 17, 17+ 14 days, 20, 23, 24, 27, 30, 33 and 36.
Patients were observed in hospital for 2 hours post vaccination for adverse events (AEs). It was planned
that if no AEs were observed after 12 patients completed six doses of vaccination, the 2-hour hospital stay
may be discontinued; however, because of the early termination of the study, this was not implemented.
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Time points were adjusted if visits were delayed to keep visits as close as possible to the 14-day
post-vaccination visits. Many of the baseline investigations were repeated throughout the follow-up period
at varying time points. The repeated tests included FBCs and differential blood counts; biochemistry
including the CK test and urinalysis; immunological monitoring [65ml of anticoagulated blood (in lithium
heparin tubes) and 5ml of clotted blood for serum would be taken for immunological monitoring];
ECG; echocardiogram (ECHO), if clinically indicated; bone marrow for immunological (CML and AML) and
disease (AML) evaluation; leukapheresis; and molecular analysis of BCR–ABL and WT1 transcripts in CML
patients and WT1 transcripts in AML patients (20ml of anticoagulated blood was taken for qPCR).
All patients were asked to consent to information about their health status being held and maintained by the
Health and Social Care Information Centre and the NHS Central Register, to enable long-term follow-up.
Outcome measures
Molecular response
Definition of the BCR–ABL response
For patients with a baseline BCR–ABL transcript level of > 11 transcripts/mg of ribonucleic acid (RNA):
l Complete molecular response: a BCR–ABL transcript level of 0 transcripts/mg of RNA with an Abelson
murine leukaemia viral oncogene homologue 1 (ABL) control level of ≥ 32,000 transcripts/mg of RNA in
two consecutive tests. These patients cannot be assessed for a major or minor response as
defined below.
For patients with a baseline BCR–ABL transcript level of ≥ 11 transcripts/mg of RNA:
l Complete molecular response: a BCR–ABL transcript level of 0 transcripts/mg of RNA, with an ABL
control level of ≥ 32,000 transcripts/mg of RNA in two consecutive tests.
l Major response: a fall of > 1-log in the breakpoint cluster region (BCR) to ABL transcript level ratio.
Confirmed in an ABL control level of ≥ 32,000 transcripts/mg of RNA in two consecutive samples at
any time during follow-up.
l Minor response: a fall of > 0.5-log in the BCR to ABL transcript level ratio. Confirmed in an ABL control
copy transcript level of ≥ 32,000 transcripts/mg of RNA in two consecutive samples at any time during
follow-up.
Definition of WT1 response
For patients with a baseline WT1 to β-glucuronidase (GUS) transcript level ratio of < 0.1%:
l Complete molecular response: 0% WT1 to GUS transcript level ratio, with a GUS control level
of ≥ 32,000 transcripts/mg of RNA; in two consecutive tests these patients cannot be assessed for
a major or minor response as defined below.
For patients with a baseline WT1 to GUS transcript level ratio of ≥ 0.1%:
l Complete molecular response: 0% WT1 to GUS transcript level ratio, with a GUS control level ≥ 32,000
transcripts/mg of RNA; in two consecutive tests.
l Major response: a fall of > 1-log in the WT1 to GUS transcript level ratio. Confirmed in a GUS control
level of ≥ 32,000 transcripts/mg of RNA in two consecutive samples at any time during follow-up.
l Minor response: a fall of > 0.5-log in the WT1 to GUS transcript level ratio. Confirmed in a GUS control
level of ≥ 32,000 transcripts/mg of RNA in two consecutive samples at any time during follow-up.
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Immunological response
Definition of validated assay by tetramer
A positive response using the validated assays by tetramer will be determined by the following criteria:
l tetramer staining at the post-vaccination time point is over the cut-off value for the specific tetramer
when the pre-vaccination baseline time point (visit number 00 or 01) is below this cut-off value or
l tetramer staining at the post-vaccination time point is more than twofold above the baseline time
point when the baseline time point measures over the cut-off value for the specific tetramer
l tetramer staining is reviewed and confirmed by at least two independent, flow cytometric-
experienced scientists.
Immunological responses may also be assessed by other research assays such as intracellular cytokine
staining and enzyme-linked immunospot. Only results produced by validated end-point assays will be
reported on.
All patients who are removed from the study for reasons other than progressive disease will be
re-evaluated at the time of treatment discontinuation.
Primary outcome
Chronic myeloid leukaemia
The primary outcome for the CML treatment group was a molecular BCR–ABL response (major or minor
response or CMR), as defined in Definition of BCR–ABL response.
Acute myeloid leukaemia
The primary outcome for the AML treatment group was time to disease progression. Disease progression
in AML is defined as disease relapse.
Secondary outcomes
Chronic myeloid leukaemia
The secondary outcomes for the CML treatment group are as follows:.
l A BCR–ABL molecular response (major response or CMR), as defined in Definition of
BCR–ABL response.
l A WT1 molecular response of (major or minor response or CMR), as defined in Definition of
WT1 response.
l Time to disease progression. Disease progression for CML patients is defined as a loss in complete
haematological response, where at least one factor falls out of the following ranges:60
¢ a white blood cell count of < 10 × 109/l
¢ basophils levels of < 5%
¢ no myelocytes, promyelocytes or myeloblasts in the differential blood count
¢ a platelet count of < 450 × 109/l
¢ a non-palpable spleen.
l Time to next treatment. A next treatment is defined as the first drug taken during the course of the
study with an indication to treat CML.
l Time to molecular response (for both BCR–ABL and WT1):
¢ measured from the beginning of TKI treatment
¢ measured from the time of obtaining informed consent.
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l Overall survival.
l Toxicity assessed according to the National Cancer Institute’s Common Terminology Criteria for Adverse
Events (CTCAE), version 4.0.1
l Pain assessment immediately after vaccination (see Appendix 1).
l Pain assessment at 48 hours post vaccination (see Appendix 2).
Acute myeloid leukaemia
The secondary outcomes for the AML treatment group are as follows:
l 2-year overall survival.
l 2-year progression-free survival (PFS).
l Overall survival.
l A WT1 molecular response (major or minor response or CMR), as defined in Definition of
WT1 response.
l Toxicity assessed according to the National Cancer Institute’s CTCAE, version 4.0.
l Pain assessment immediately after vaccination.
l Pain assessment at 48 hours post vaccination.
Human leucocyte antigen A2-positive patients only (chronic myeloid
leukaemia and acute myeloid leukaemia)
The secondary outcomes for only the HLA A2+ patients are as follows:
l Immune response to WT1 epitope-specific T cells in blood and/or bone marrow, using validated assays
by tetramer staining. A positive response using the validated assays by tetramer staining is defined in
Definition of validated assay by tetramer.
l Number of WT1-specific T-cells after peptide challenge to the skin (wherever assessment is feasible).
l Immune response to FrC, evaluated using validated assays by enzyme-linked immunosorbent
assay (ELISA).
l Number of humoral responses (B lymphocytes) to the vaccine components evaluated using ELISA.
Sample size
Original sample size
For sample size calculation, we used Simon’s optimal Phase-II trial design for clinical development of
therapeutic cancer vaccines.60,61 This would allow us to undertake a ‘start/stop’ evaluation once 12 patients
had been enrolled into each vaccination group of the study and had been evaluated to 6 months
(molecular monitoring).
If one or more responders were observed in the 12 initial patients, this particular vaccination group would
be extended to 37 patients. This would allow the study to distinguish between p0= 5% (standard
response) and p1= 20% (expected response) with α= 0.1% (two-sided) and β= 0.10, where p0 is the
probability of a clinically uninteresting true response rate and p1 is the probability of a sufficiently
promising true response rate. This gives a less than 10% chance of rejecting a useful vaccine, with error
probability limits of α 0.10 and β < 0.10, even if the true response rate were to be p1= 20%.
If no molecular responses were seen in the first 12 CML or AML patients, recruitment would have ceased
for this patient group, as there will not be sufficient clinical interest to pursue the trial further. This optimal
design had an expected sample size under H0 (the null hypothesis) of 24 and a maximum sample size of
37 in each patient group (AML and CML).
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Revised sample size
The sample size was revised in line with the change in trial design from Simon’s two-stage60 to
A’Hern’s one-stage trial design.59 This was approved in version 6 of the protocol on 8 November 2012
(see Table 1).
Chronic myeloid leukaemia
The sample size for the HLA A2+ group had been determined using A’Hern’s single-stage trial design59 and
the primary outcome measure of molecular response (BCR–ABL or WT1 transcript level) for CML patients.
A molecular response (BCR–ABL or WT1 transcript level) rate of 20% would imply that the vaccine clearly
warrants further investigation. A molecular response rate of ≤ 5% would be unacceptable and would
indicate that the vaccine does not warrant further investigation. The probability of obtaining a false-positive
result, α (i.e. incorrectly accepting for further trial a treatment that has a true response rate of 5%), was set
at 10%. The probability of a false-negative result, β (i.e. incorrectly rejecting for further trial a treatment with
a true response rate of 20%), was set at 10%. Using these parameters (α= 0.1, β= 0.1, p0= 5%, p1= 20%),
32 HLA A2+ patients needed to be recruited to the trial. The drop-out rate was expected to be < 10% and
hence a total of 36 patients would be recruited. The control arm consisted of all eligible and consenting
patients who were HLA A2–.
This trial needed to observe a minimum of four molecular responders out of 32 patients in order to
provide evidence that the vaccine warrants further investigation.
Acute myeloid leukaemia
The sample size calculation for the AML treatment group was based on A’Hern’s single-stage design59 and
the primary outcome measure of PFS at 2 years post vaccination.
A PFS rate of 50% at 2 years post vaccination would indicate that the vaccine warrants further
investigation. A PFS rate of ≥ 30% at 2 years post vaccination would be unacceptable and would indicate
the vaccine does not warrant further investigation. The probability of obtaining a false-positive result,
α (i.e. incorrectly accepting for further trial a treatment that has a true PFS rate of 30%), was set at 10%.
The probability of a false-negative result, β (i.e. incorrectly rejecting for further trial a treatment with a true
PFS rate of 50%) was set at 10%. Using these parameters, α= 0.1, β= 0.1, p0= 30%, p1= 50%, 39 HLA
A2+ patients needed to be recruited to the trial. The dropout rate was expected to be > 10%. The control
arm consisted of all eligible and consenting patients who were HLA A2–.
This trial needed to observe a minimum of 16 out of 39 patients who are progression free and alive
at 2 years in order to provide evidence that the vaccine warrants further investigation.
Interim analyses and stopping guidelines
Following the original trial design of Simon’s optimal phase II trial design,60 there was a ‘start/stop’
evaluation once 12 patients had been enrolled into the trial (Figure 3). The molecular data for these
patients will be evaluated (molecular monitoring). If no molecular responses are seen in the first
12 vaccinated patients with CML, recruitment will cease for CML and will not begin for AML,
as there will not be sufficient clinical interest to pursue further. After the change in trial design to A’Hern’s
one-stage design,59 this stopping evaluation was no longer in required.
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A Data Monitoring and Ethics Committee (DMEC) was convened on behalf of, and with input from,
the Trial Management Group. The committee’s remit was to meet at regular intervals to review the safety
listings and recruitment and to make a recommendation on whether or not to continue beyond 12 patients
in the CML and AML cohorts. Unplanned DMEC meetings were to be called if required during the study.
In addition, the DMEC would review any cases of CTCAE grade 3 adverse reactions, possibly or likely to
be related to vaccination to assess if there were sufficient reason to suspend or terminate the study.
Statistical analysis
All trial analyses and reporting were carried out following the Consolidated Standards of Reporting Trials




The analyses of the molecular responses were performed on all patients with molecular data at a minimum
of two post-baseline time points (HLA A2+ patients must also have received at least one dose of
the vaccine).
Immunological analysis
To be evaluable for an immunological response, HLA A2+ patients must have received at least one dose of
the vaccine and the immunological testing must have been available until at least week 8 post first dose.
Safety analysis
For safety analyses, all HLA A2+ patients who received at least one trial drug administration were
evaluable for toxicity. All controls were included in the safety analyses, where relevant.
Recruit 12 patients to
CML-vaccinated group
Is there at least one CML




Continue CML recruitment. Stop
recruitment once 37 evaluable 
CML patients have been recruited
Trial stops
Open up recruitment to AML
patients. Recruit 43 patients to
AML-vaccinated group
No
Monitor molecular data (all time points during trial follow-up)
for the first 12 CML-vaccinated patients
FIGURE 3 Flow diagram showing the original two-stage design for the CML patient group.
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Other analysis (intention-to-treat population)
For all other analyses, an intention-to-treat (ITT) principle (i.e. the planned treatment regimen) was used,
which included all registered patients who obtained HLA A2+ status.
Preliminary analyses
Disposition of patients and follow-up information on the ITT population were analysed separately for
HLA A2+ and HLA A2– patients (see Figure 4 and Table 2). Major protocol deviations were also listed
for the ITT population (see Box 1).
Patient characteristics recorded at baseline, including the patient’s age, gender, ECHO result and WHO
performance status, were summarised by HLA A2 status for the ITT population (see Table 3). In addition,
baseline BCR–ABL and WT1 molecular data were analysed separately for the molecular analysis population
and summarised by HLA A2 status (see Tables 4 and 5).
Dosing information on pre-trial imatinib treatment was summarised by HLA A2 status for the ITT
population (see Table 6).
Treatment analyses
Vaccination administration and electroporation failure summarises were presented for the ITT population
(HLA A2+ patients only), together with details of any reasons for premature withdrawals from treatment
(see Tables 7–9).
Safety analyses
Serious adverse events (SAEs), including a SAE summary and listing of SAEs by system organ class and
CTCAE term, were presented by HLA A2 status for the safety analysis population (Tables 10 and 11).
In addition, a complete SAE listing was provided for the safety analysis population (see Table 12).
Information on all AEs was also presented by HLA A2 status for the safety analysis population,
which comprised a summary by worst CTCAE grade recorded across the following type of AEs:
l all AEs (see Table 13)
l cardio-related AEs (see Table 14)
l renal-related AEs (see Table 15)
l bone marrow-related AEs (see Table 16)
l other-related AEs (see Table 17).
Fisher’s exact test was used to compare differences in rates of toxicity in CML patients with controls for the
safety population. No adjustment was made for multiple testing and, therefore, borderline significance
should not be overinterpreted.
A list of all AEs was also presented for the safety analysis population (see Table 18). In addition, any
concomitant medications taken because of pain within 48 hours following vaccination were summarised
for HLA A2+ patients only in the safety analysis population (see Table 19).
Primary analyses
The primary outcome is a BCR–ABL molecular response (major or minor response or CMR), which was
summarised for the molecular analysis population by HLA A2 status (see Table 20).
Secondary analyses
Secondary outcomes carried out on the molecular analysis population included:
l BCR–ABL (major response or CMR), summarised by HLA A2 status (see Table 21)
l WT1 (major or minor response or CMR), summarised by HLA A2 status (see Table 22).
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In addition, the following time-to-event secondary outcomes were also analysed by HLA A2 status for
the ITT population:
l time to last follow-up (see Table 23 and Figure 5)
l time to progression or death (see Table 24 and Figure 6)
l time to death (see Table 25 and Figure 7)
l time to next treatment (see Table 26 and Figure 8).
In each case, the median time to event was presented along with time to event listings, a log-rank test,
results from an unadjusted Cox proportional hazards model with alpha set at the 10% two-sided level
and a Kaplan–Meier plot.
Time to a BCR–ABL response (major or minor or CMR) and time to a WT1 response (major or minor
or CMR) from the beginning of inhibitor treatment and also from the date of informed consent were also
analysed using a similar approach for the molecular analysis population, together with the duration of
BCR–ABL and WT1 responses (see Table 27 and Figure 9, and Table 28 and Figure 10, respectively).
Pain assessment information recorded immediately after vaccination and recorded 48 hours post
vaccination were summarised in terms of the median pain score recorded and the worst pain score
recorded for HLA A2+ patients in the ITT population (see Tables 29 and 30, respectively).
Immunological analyses
The immunological analyses carried out on vaccinated HLA A2+ patients included:
l anti-FrC antibody in serum, as evaluated by a validated ELISA
l WT1-specific T-cell responses in blood and bone marrow, as evaluated by a validated WT1
tetramer assay.
The ELISA acceptance criteria included a post-vaccination time point level > twofold increase, as well as
significantly greater levels of anti-FrC antibody compared with pre-vaccination baseline (p< 0.05,
Dunnett’s multiple comparisons test).
The WT1 tetramer acceptance criteria included a post-vaccination time point level > twofold over baseline
and confirmed by three independent flow cytometric experts.
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Chapter 4 Trial results
The intention to recruit 39 AML patients was not realised because of the early termination of the trial.The information included in this section only relates to patients in the CML treatment group.
Recruitment
Below is a summary of the recruitment milestones in the WIN trial:
l Southampton (first site) opened: 1 February 2011.
l Hammersmith opened: 9 May 2011.
l Exeter opened: 21 November 2011.
l First patient registered: 1 June 2011.
l Chronic myeloid leukaemia arm closed: 26 February 3013.
l Last patient, last visit: 31 July 2014.
l Trial termination: 25 March 2014.
Flow of participants through the trial
A total of 91 CML patients were assessed for eligibility for entry into the WIN trial and 23 CML patients
were registered. Of these, 13 patients were HLA A2+ and 12 out of 13 began vaccination with a control
group of nine HLA A2– patients.
Twelve HLA A2+ patients were vaccinated and 12 out of 12 as well as nine out of nine control patients
were included in both the safety and molecular analyses. Four vaccinated and two control patients
completed the study protocol treatment. The other patients either withdrew consent (n= 11) or underwent
modification of their TKI treatment, thus requiring study termination.
Only one AML patient was assessed for eligibility for entry into the WIN trial, but decided not to enter
into the trial.
Figure 4 shows the CONSORT diagram for the CML group only.
Major protocol deviations
There were no major protocol deviations. Box 1 summarises the protocol deviations that occurred
during the trial.
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Excluded (n = 68)
• Not eligible, n = 47
• Patient choice, n = 7
• Other, n = 2
• Unknown, n = 12
Excluded from safety
analyses (n = 1)
• Did not receive any 
   vaccinations, n = 1




Completed the trial (n = 4)
Withdrawn from trial (n = 9)
• PI’s decision, n = 1
• Withdrawal of consent, n = 6
• Imatinib dose decreased, n = 2
Included in safety analyses
(n = 12)




Completed the trial (n = 2)
Withdrawn from trial (n = 7)
• Withdrawal of consent, n = 5
• Changed to dasatinib, n = 1
• Other medical urgent issues, n = 1
Included in safety analyses
(n = 9)
Excluded from molecular
analyses (n = 1)
• Insufficient molecular
data available, n = 1
Excluded (n = 1)
• Achieved CMR, n = 1
Registered
(n = 23)
CML assessed for eligibility
(n = 91)
HLA A2 status obtained
(ITT population; n = 22)
FIGURE 4 Consolidated Standards of Reporting Trials flow chart (CML group only).
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TABLE 2 Withdrawals from trial: ITT population
Characteristic
HLA A2+ (n= 13),
n (%)




Number who completed the trial 4 (30.8) 2 (22.2) 6 (27.3)
Number who discontinued the trial 9 (69.2) 7 (77.8) 16 (72.7)
PI’s decisiona 1 (11.1) 0 1 (6.3)
Withdrawal of consenta 6 (66.7) 5 (71.4) 11 (68.8)
Difficulty in complying with study visits because of
work commitments and because patient found
vaccinations distressingb
1 (16.7) 0 1 (9.1)
As there are going to be no more vaccinationsb 1 (16.7) 0 1 (9.1)
Good response, not keen on the number of visitsb 1 (16.7) 0 1 (9.1)
Patient choiceb 3 (50.0) 5 (100) 8 (72.7)
Othera 2 (22.2) 2 (28.6) 4 (25.0)
Changed to dasatinibc 0 1 (50.0) 1 (25.0)
Imatinib dose decreased to 300mg o.d.c 1 (50.0) 0 1 (25.0)
Imatinib dose reduced to 400mg o.d.c 1 (50.0) 0 1 (25.0)
Other medical urgent issuesc 0 1 (50.0) 1 (25.0)
Time from consent date to end of study (months)







Range 5.42–33.48 3.94–23.00 3.94–33.48
IQR, interquartile range; o.d., once daily.
a Denominator is the number of patients in the ITT population who discontinued the trial.
b Denominator is the number of patients in the ITT population who discontinued the trial owing to a withdrawal
of consent.
c Denominator is the number of patients in the ITT population who discontinued the trial owing to another reason.
BOX 1 Summary of protocol deviations
Protocol deviation
Missed patient visits:
l 2-C-008: visit 7 and visit 8.
l 2-C-015: visit 3 and visit 4.
l 2-C-016: visit 1 and visit 2.
l 2-C-020: visit 6.
Immunological blood sample volumes below the protocol requirements.
1-C-023: baseline molecular sample taken, but not sent to central laboratory.
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Characteristics of the trial sample
Tables 3–5 detail the baseline characteristics of the trial sample. The distribution of patient baseline
characteristics was fully consistent with the expected distribution. The arms appear well balanced,
within the limits of a small sample size.
As expected from the entry criteria of the trial, the BCR–ABL transcript levels were low. WT1 transcripts
were detected in all but one patient, in line with published data sets.
TABLE 3 Baseline characteristics: ITT population
Characteristic HLA A2+ (n= 13) HLA A2– (n= 9) Total (n= 22)
Gender, n (%)a
Male 6 (46.2) 4 (50.0) 10 (47.6)
Female 7 (53.8) 4 (50.0) 11 (52.4)
Missing 0 (0) 1 (11.1)b 1 (4.5)
WHO performance status, n (%)a
0: Asymptomatic 13 (100) 8 (100%) 21 (100)
1: Symptomatic but completely ambulatory 0 (0) 0 (0) 0 (0)
Missing 0 (0) 1 (11.1)b 1 (4.5)
ECHO result, n (%)a
Normal 10 (76.9) NAc 10 (76.9)
Abnormal 0 (0) NAc 0 (0)
Not done 3 (23.1) NAc 3 (23.1)
Age at baseline (years)
n 13 9 22
Median (IQR) 52 (42–60) 56 (51–63) 53 (46–63)
Range 23–66 42–73 23–73
IQR, interquartile range; NA, not applicable.
a Percentages are based on the number with non-missing data for each characteristic.
b No baseline information was received for patient 1-C-003, who withdrew from the trial early owing to ‘other urgent
medical issues’.
c ECHO result recorded for HLA A2+ patients only.
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TABLE 4 Baseline BCR–ABL molecular data: molecular analysis population
Characteristic HLA A2+ (n= 12) HLA A2– (n= 8) Total (n= 20)
Transcript type, n (%)
e13/e14a2 0 (0) 1 (12.5) 1 (5.0)
e13a2 2 (16.7) 3 (37.5) 5 (25.0)
e13a2/e14a2 0 (0) 1 (12.5) 1 (5.0)
e14a2 7 (58.3) 2 (25.0) 9 (45.0)
Unknown 3 (25.0) 1 (12.5) 4 (20.0)
Result, n (%)
Positive 12 (100) 8 (100) 20 (100)
Undetectable 0 (0) 0 (0) 0 (0)
Failed 0 (0) 0 (0) 0 (0)
Transcript level (transcripts/mg of RNA)
n 12 8 20
Median (IQR) 6.5 (2.5–12.5) 16.5 (7.0–29.5) 7.0 (4.0–23.5)
Range 2–42 1–68 1–68
ABL control (transcripts/mg of RNA)
n 12 8 20
Median (IQR) 28,100 (15,900–46,100) 30,950 (20,450–69,300) 29,550 (18,150–47,450)
Range 14,300–61,800 14,300–97,900 14,300–97,900
BCR to ABL transcript level ratio
n 12 8 20
Median (IQR) 0.021 (0.013–0.056) 0.036 (0.023–0.079) 0.027 (0.015–0.061)
Range 0.003–0.098 0.005–0.117 0.003–0.117
IQR, interquartile range.
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Treatment adherence
Pre-trial information is described in Table 6 and treatment adherence is described in Tables 7–9.
Maintenance imatinib treatment was given throughout the trial (see Table 6). Table 6 also describes the
duration of pre-trial treatment with imatinib. A course of six pairs of vaccinations (with p.DOM–WT1-37
and p.DOM–WT1-126, respectively) were planned for weeks 0, 4, 8, 12, 16 and 20, followed by
maintenance vaccinations. Median vaccination was the expected 12 doses, with a range of 3–6 pairs of
vaccinations delivered. Only one patient went on to receive one further set of maintenance vaccinations.
There were two technical failures of electroporation delivery in the same patient at one vaccination time
point (Table 8). Ten out of 12 patients completed all six pairs of vaccination to week 20. Two patients
withdrew consent for further injections after three doses of the vaccine (see Table 9).
TABLE 5 Baseline WT1 molecular data: molecular analysis population
Characteristic HLA A2+ (n= 12) HLA A2– (n= 8) Total (n= 20)
Result, n (%)
Positive 12 (100) 7 (87.5) 19 (95.0)
Undetectable 0 (0) 1 (12.5) 1 (5.0)
Failed 0 (0) 0 (0) 0 (0)
Transcript level (transcripts/mg of RNA)
n 12 8 20
Median (IQR) 5.9 (2.0–9.5) 3.0 (1.5–7.5) 4.5 (2.0–9.5)
Range 1–83 0–74 0–83
GUS control (transcripts/mg of RNA)
n 12 8 20
Median (IQR) 40,027.2 (23,402.5–59,431.5) 45,856.9 (36,828.5–59,618.8) 41,656.9 (31,270.0–59,431.5)
Range 16,828.8–99,100.0 22,644.4–12,3530.8 16,828.8–123,530.8
WT1 to GUS transcript level ratio
n 12 8 20
Median (IQR) 0.011 (0.006–0.048) 0.004 (0.003–0.019) 0.010 (0.003–0.022)
Range 0.002–0.294 0.000–0.025 0.000–0.294
IQR, interquartile range.
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TABLE 6 Pre-trial imatinib dosing information: ITT population
Characteristic HLA A2+ (n= 13) HLA A2– (n= 9) Total (n= 22)
Received pre-trial imatinib,a n (%) 12 (92.3) 8 (88.9) 20 (90.9)
Maximum imatinib dose receivedb
300mg o.d. 1 (8.3) 0 1 (5.0)
400mg o.d. 6 (50.0) 4 (50.0) 10 (50.0)
500mg o.d. 0 1 (12.5) 1 (5.0)
600mg o.d. 4 (33.3) 1 (12.5) 5 (25.0)
800mg o.d. 1 (8.3) 2 (25.0) 3 (15.0)
Imatinib duration (months)c
n 12 8 20
Median (IQR) 89.1 (69.8–101.7) 79.1 (67.9–98.0) 85.0 (69.8–100.8)
Range 28.1–110.1 27.8–105.6 27.8–110.1
Imatinib duration (years)d
n 12 8 20
Median (IQR) 7.4 (5.8–8.5) 6.6 (5.7–8.2) 7.1 (5.8–8.4)
Range 2.3–9.2 2.3–8.8 2.3–9.2
IQR, interquartile range; o.d., once daily.
a Percentages are based on the number with non-missing treatment data.
b Percentages are based on the number receiving pre-trial imatinib treatment.
c Imatinib duration defined as time from the earliest start date of imatinib pre-trial to the stop date of imatinib pre-trial
(in months).
d Imatinib duration defined as time from the earliest start date of imatinib pre-trial to the stop date of imatinib pre-trial
(in years).
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TABLE 7 Vaccination treatment summary: ITT population – HLA A2+ patients only
Characteristic HLA A2+ (n= 13)
Received treatment,a n (%) 12 (92.3)
Initial p.DOM–WT1-37 or p.DOM–WT1-126 vaccination administration
No vaccines administeredb 0 (0)
At least one vaccine administeredb 12 (100)
At least one p.DOM–WT1-37 vaccination administered where no p.DOM–WT1-126 vaccination
administered (or vice versa)b
0 (0)
Number of initial p.DOM–WT1-37 or p.DOM–WT1-126 vaccinations received
n 12
Median (IQR) 6 (6–6)
Range 3–6
Proceeded onto additional vaccinations,a n (%) 1 (7.7)
Additional p.DOM–WT1-37 or p.DOM–WT1-126 vaccinations
No vaccines administeredc 0 (0)
At least one vaccine administeredc 1 (100)
At least one p.DOM–WT1-37 vaccination administered where no p.DOM–WT1-126 vaccination
administered (or vice versa)c
0 (0)
Number of additional p.DOM–WT1-37 or p.DOM–WT1-126 vaccinations received
n 1
Median (IQR) 1 (1–1)
Range 1–1
Received treatment,a n (%) 12 (92.3)
Any (initial or additional) p.DOM–WT1-37 or p.DOM–WT1-126 vaccinations
No vaccines administeredb 0 (0)
At least one vaccine administeredb 12 (100)
At least one p.DOM–WT1-37 vaccination administered where no p.DOM–WT1-126 vaccination
administered (or vice versa)b
0 (0)
Number of any (initial or additional) p.DOM–WT1-37 or p.DOM–WT1-126 vaccinations received
n 12
Median (IQR) 6 (6–6)
Range 3–7
IQR, interquartile range.
a Percentages are based on the number with non-missing treatment data.
b Percentages are based on the number receiving initial treatment.
c Percentages are based on the number proceeding onto additional treatment.
Notes
Initial vaccinations= vaccinations administered on weeks 0, 4, 8, 12, 16 or 20.
Additional vaccinations= vaccinations administered on week 32, or month 11 day 0, month 14 day 0, month 17 day 0,
month 20 day 0 or month 23 day 0.
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TABLE 8 Electroporation treatment summary: ITT population – HLA A2+ patients only
Characteristic HLA A2+ (n= 13)
Received treatment,a n (%) 12 (92.3)
Initial p.DOM–WT1-37 or WT1-126 electroporation failures
No electroporation failures 10 (83.3)
At least one electroporation failure 2 (16.7)
Electroporation failure details
Electroporation failure in initial p.DOM–WT1-37 vaccinationb 1 (50.0)
Electroporation failure in initial p.DOM–WT1-126 vaccinationc 1 (50.0)
Initial p.DOM–WT1-37 or WT1-126 electroporation failures
n 12
Median (IQR) 0 (0–0)
Range 0–1
Proceeded onto additional vaccinations,d n (%) 1 (7.7)
Additional p.DOM–WT1-37 or p.DOM–WT1-126 electroporation failure
No electroporation failures 1 (100)
At least one electroporation failure 0 (0)
Additional p.DOM–WT1-37 or 126 electroporation failures
n 0
Median (IQR) 0 (0–0)
Range 0–0
Received treatment,e n (%) 12 (92.3)
Any (initial or additional) p.DOM–WT1-37 or WT1-126 electroporation failures
No electroporation failures 10 (83.3)
At least one electroporation failure 2 (16.7)
Electroporation failure details:
Electroporation failure in initial p.DOM–WT1-37 vaccinationb 1 (50.0)
Electroporation failure in initial p.DOM–WT1-126 vaccinationc 1 (50.0)
Any (initial or additional) p.DOM–WT1-37 or WT1-126 electroporation failures
n 12
Median (IQR) 0 (0–0)
Range 0–1
IQR, Interquartile range.
a Percentages are based on the number receiving initial treatment.
b Initial p.DOM–WT1-37 vaccination location was the same as the previous vaccination in the right thigh. Initial 126
vaccination location was the same as the previous vaccination in the left thigh.
c Initial p.DOM–WT1-37 vaccination location was the same as the previous vaccination in the right arm. Initial
p.DOM–WT1-126 vaccination location was the same as the previous vaccination in the left arm.
d Percentages are based on the number proceeding onto additional treatment.
e Percentages are based on the number with non-missing treatment data.
Notes
Initial electroporation: electroporation administered on weeks 0, 4, 8, 12, 16 or 20.
Additional electroporation: electroporation administered on week 32, or month 11 day 0, month 14 day 0, month 17
day 0, month 20 day 0 or month 23 day 0.
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Details of SAEs are provided in Tables 10–12. No vaccine-related SAEs were observed. Three SAEs were
observed in the control group and are not vaccine related.
Adverse events
In the vaccine group, 11 grade 1–3 AEs were observed, compared with nine grade 1–3 AEs in the control
group (Table 13). Of these AEs, palpitations in one vaccinated patient were of special interest (Table 14).
In one patient, 12 grade 1–3 renal AEs were documented (pre-existing grade 1 renal dysfunction), with no
such AEs observed in the control group (Table 15). No haematological toxicities were observed (Table 16).
A range of mild to moderate AEs was observed (Table 17). No detectable significance was observed
between the vaccination and observation arms.
Table 18 provides a complete list of all AEs for the safety analysis population.
Concomitant medications taken because of pain within 48 hours
of vaccination
Two patients used painkillers after vaccination/electroporation, with good symptomatic relief (Table 19).
No new clinical insights beyond the pre-trial data on electroporation were observed.
TABLE 9 Premature withdrawals from treatment: ITT population – HLA A2+ patients only
Characteristic HLA A2+ (n= 13), n (%)
Received treatmenta 12 (92.3)
Patients who received all six initial vaccinationsb 10 (83.3)
Patients who did not receive all six initial vaccinationsb 2 (16.7)
Withdrew consent (from treatment only)c 2 (100)
Patients who proceeded to receive additional vaccinationsb 1 (7.7)
Patients who received all six additional vaccinationsd 0 (0)
Patients who did not receive all six additional vaccinations 1 (100)
Withdrew consent (from trial)e 1 (100)
a Percentages are based on the number with non-missing treatment data.
b Percentages are based on the number receiving treatment.
c Percentages are based on the number who did not receive all six initial vaccinations.
d Percentages are based on the number proceeding onto additional treatment (see Chapter 3, Trial interventions).
e Percentages are based on the number who did not receive all six additional vaccinations.
Notes
Initial vaccinations: vaccinations administered on weeks 0, 4, 8, 12, 16 or 20.
Additional vaccinations: vaccinations administered on week 32, or month 11 day 0, month 14 day 0, month 17 day 0,
month 20 day 0 or month 23 day 0.
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TABLE 10 Serious adverse event summary: safety analysis population
Characteristic HLA A2+ (n= 12) HLA A2– (n= 9) Total (n= 21)
Total number of SAEs, n (%) 0 (0) 3 3
Number of patients experiencing
at least one SAE,a n (%)
0 (0) 1 (11.1) 1 (4.8)
PI assessment,b n (%)
SUSAR 0 (0) 0 (0) 0 (0)
SAR 0 (0) 0 (0) 0 (0)
SAE 0 (0) 3 (100) 3 (100)
Clinical reviewer assessment,b n (%)
SUSAR 0 (0) 0 (0) 0 (0)
SAR 0 (0) 0 (0) 0 (0)
SAE 0 (0) 3 (100) 3 (100)
Grade,b n (%)
Mild 0 (0) 0 (0) 0 (0)
Moderate 0 (0) 2 (66.7) 2 (66.7)
Severe 0 (0) 1 (33.3) 1 (33.3)
Life-threatening 0 (0) 0 (0) 0 (0)
Death related to AE 0 (0) 0 (0) 0 (0)
Why was the event serious?,b n (%)
Resulted in death 0 (0) 0 (0) 0 (0)
Life-threatening 0 (0) 0 (0) 0 (0)
Required hospitalisation or prolongation of
existing hospitalisation
0 (0) 3 (100) 3 (100)
Persistent or significant disability/incapacity 0 (0) 0 (0) 0 (0)
Congenital anomaly/birth defect 0 (0) 0 (0) 0 (0)
SAR, serious adverse reaction; SUSAR; suspected unexpected serious adverse reaction.
a Percentages are based on the number of patients in the safety analysis population.
b Percentages are based on the total number of SAEs.
TABLE 11 Summary of SAEs by system organ class and CTCAE term: safety analysis population
CTCAE, version 4, system organ class/terma HLA A2+ (n= 12) HLA A2– (n= 9) Total (n= 21)
Gastrointestinal disorders,b n (%) 0 (0) 3 (100) 3 (100)
Abdominal pain,c n (%) 0 (0) 3 (100) 3 (100)
a Percentages are based on the total number of SAEs.
b CTCAE, version 4, system organ class.
c CTCAE, version 4, term.
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TABLE 13 Overall worst CTCAE grade across all AEs: safety analysis populationa,b
Characteristic HLA A2+ (n= 12) HLA A2– (n= 9) Total (n= 21)
Worst CTCAE grade experienced, n (%)
None 1 (8.3) 0 (0) 1 (4.8)
Grade 1: mild 6 (50.0) 4 (44.4) 10 (47.6)
Grade 2: moderate 5 (41.7) 4 (44.4) 9 (42.9)
Grade 3: severe 0 (0) 1 (11.1) 1 (4.8)
Grade 4: life-threatening 0 (0) 0 (0) 0 (0)
Grade 5: death related to an AE 0 (0) 0 (0) 0 (0)
At least one severe (CTCAE grade 3 or above) AE 0 (0) 1 (11.1) 1 (4.8)
a If a patient experienced more than one AE with different CTCAE grades, then the worst CTCAE grade is counted in
this table.
b Multiple events per patient are counted once.
TABLE 14 Worst CTCAE grade for cardio-related AEs: safety analysis populationa,b,c
Characteristic HLA A2+ (n= 12) HLA A2– (n= 9) Total (n= 21) p-valued
Worst CTCAE grade for cardio-related AEs experienced, n (%)
None 11 (91.7) 9 (100) 20 (95.2) –
Grade 1: mild 0 (0) 0 (0) 0 (0) –
Grade 2: moderate 1 (8.3) 0 (0) 1 (4.8) –
Grade 3: severe 0 (0) 0 (0) 0 (0) –
Grade 4: life-threatening 0 (0) 0 (0) 0 (0) –
Grade 5: death related to AE 0 (0) 0 (0) 0 (0) –
At least one severe (CTCAE grade 3 or above)
cardio-related AE
0 (0) 0 (0) 0 (0) –
CTCAE, version 4, term, n (%)
Palpitations 1 (8.3) 0 1 (4.8) > 0.999
a If a patient experienced more than one cardio-related AE with different CTCAE grades, then the worst CTCAE grade is
counted in this table.
b If a patient experienced more than one cardio-related AE with the same worst CTCAE grade, then they are counted
once in the first section and once under each nature of AE.
c Multiple events per patient are counted once.
d Fisher’s exact tests were calculated to compare differences between HLA A2+ and HLA A2– groups for each type of
CTCAE term.
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TABLE 15 Worst CTCAE grade for renal-related AEs: safety analysis populationa,b,c
Characteristic HLA A2+ (n= 12) HLA A2– (n= 9) Total (n= 21) p-valued
Worst CTCAE grade for renal-related AEs experienced, n (%)
None 8 (66.7) 9 (100) 17 (81.0) –
Grade 1: mild 3 (25.0) 0 (0) 3 (14.3) –
Grade 2: moderate 1 (8.3) 0 (0) 1 (4.8) –
Grade 3: severe 0 (0) 0 (0) 0 (0) –
Grade 4: life-threatening 0 (0) 0 (0) 0 (0) –
Grade 5: death related to AE 0 (0) 0 (0) 0 (0) –
At least one severe (CTCAE grade 3 or above)
renal-related AE
0 (0) 0 (0) 0 (0) –
CTCAE, version 4, term, n (%)
CK increased 1 (8.3) 0 (0) 1 (4.8) > 0.999
Renal and urinary disorders, other 1 (8.3) 0 (0) 1 (4.8) > 0.999
Renal calculi 1 (8.3) 0 (0) 1 (4.8) > 0.999
Urinary tract pain 1 (8.3) 0 (0) 1 (4.8) > 0.999
a If a patient experienced more than one renal-related AE with different CTCAE grades, then the worst CTCAE grade is
counted in this table.
b If a patient experienced more than one renal-related AE with the same worst CTCAE grade, then they are counted once
in the first section and once under each nature of AE.
c Multiple events per patient are counted once.
d Fisher’s exact tests were calculated to compare differences between HLA A2+ and HLA A2– groups for each type of
CTCAE term.
TABLE 16 Worst CTCAE grade for bone marrow-related AEs: safety analysis populationa,b,c
Characteristic HLA A2+ (n= 12) HLA A2– (n= 9) Total (n= 21)
Worst CTCAE grade for bone marrow-related AEs experienced, n (%)
None 12 (100) 9 (100) 21 (100)
Grade 1: mild 0 (0) 0 (0) 0 (0)
Grade 2: moderate 0 (0) 0 (0) 0 (0)
Grade 3: severe 0 (0) 0 (0) 0 (0)
Grade 4: life-threatening 0 (0) 0 (0) 0 (0)
Grade 5: death related to AE 0 (0) 0 (0) 0 (0)
At least one severe (CTCAE grade 3 or above)
bone marrow-related AE
0 (0) 0 (0) 0 (0)
a If a patient experienced more than one bone marrow-related AE with different CTCAE grades, then the worst CTCAE
grade is counted in this table.
b If a patient experienced more than one bone marrow-related AE with the same worst CTCAE grade, then they are
counted once in the first section and once under each nature of AE.
c Multiple events per patient are counted once.
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TABLE 17 Worst CTCAE grade for other-related AEs: safety analysis populationa,b,c,d
Characteristic HLA A2+ (n= 12) HLA A2– (n= 9) Total (n= 21) p-valuee
Worst CTCAE grade for other-related AEs experienced, n (%)
None 1 (8.3) 0 1 (4.8) –
Grade 1: mild 7 (58.3) 4 (44.4) 11 (52.4) –
Grade 2: moderate 4 (33.3) 4 (44.4) 8 (38.1) –
Grade 3: severe 0 (0) 1 (11.1) 1 (4.8) –
Grade 4: life-threatening 0 (0) 0 (0) 0 (0) –
Grade 5: death related to AE 0 (0) 0 (0) 0 (0) –
At least one severe (CTCAE grade 3 or above)
other-related AE
0 (0) 1 (11.1) 1 (4.8) –
CTCAE, version 4, term, n (%)
Abdominal pain 0 (0) 1 (11.1) 1 (4.8) 0.429
Anorexia 0 (0) 1 (11.1) 1 (4.8) 0.429
Bloating 1 (8.3) 0 (0) 1 (4.8) > 0.999
Bone pain 0 (0) 1 (11.1) 1 (4.8) 0.429
Bruising 2 (16.7) 0 (0) 2 (9.5) 0.486
Cough 1 (8.3) 2 (22.2) 3 (14.3) 0.553
Depression 1 (8.3) 0 (0) 1 (4.8) > 0.999
Diarrhoea 1 (8.3) 1 (11.1) 2 (9.5) > 0.999
Dyspepsia 1 (8.3) 0 (0) 1 (4.8) > 0.999
Ear and labyrinth disorders, other 1 (8.3) 0 (0) 1 (4.8) > 0.999
Oedema limbs 1 (8.3) 0 (0) 1 (4.8) > 0.999
Epistaxis 1 (8.3) 0 (0) 1 (4.8) > 0.999
Eye disorders, other 2 (16.7) 1 (11.1) 3 (14.3) > 0.999
Eye infection 1 (8.3) 0 (0) 1 (4.8) > 0.999
Fatigue 4 (33.3) 0 (0) 4 (19.0) 0.104
Headache 0 (0) 2 (22.2) 2 (9.5) 0.171
Hypotension 1 (8.3) 0 (0) 1 (4.8) > 0.999
Injury, poisoning and procedural
complications, other
2 (16.7) 0 (0) 2 (9.5) 0.486
Musculoskeletal and connective tissue
disorders, other
1 (8.3) 0 (0) 1 (4.8) > 0.999
Myalgia 3 (25.0) 0 (0) 3 (14.3) 0.229
Nail infection 0 (0) 1 (11.1) 1 (4.8) 0.429
Nausea 1 (8.3) 0 (0) 1 (4.8) > 0.999
continued
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TABLE 17 Worst CTCAE grade for other-related AEs: safety analysis populationa,b,c,d (continued )
Characteristic HLA A2+ (n= 12) HLA A2– (n= 9) Total (n= 21) p-valuee
Nervous system disorders, other 1 (8.3) 2 (22.2) 3 (14.3) 0.553
Pain in extremity 1 (8.3) 0 (0) 1 (4.8) > 0.999
Respiratory, thoracic and mediastinal
disorders, other
0 (0) 1 (11.1) 1 (4.8) 0.429
Skin and subcutaneous tissue disorders, other 2 (16.7) 1 (11.1) 3 (14.3) > 0.999
Skin ulceration 0 (0) 1 (11.1) 1 (4.8) 0.429
Tooth infection 0 (0) 1 (11.1) 1 (4.8) 0.429
Upper respiratory infection 2 (16.7) 5 (55.6) 7 (33.3) 0.159
Vomiting 1 (8.3) 1 (11.1) 2 (9.5) > 0.999
Watering eyes 0 (0) 1 (11.1) 1 (4.8) 0.429
a Other AEs correspond to AEs that are not cardio, renal or bone marrow related.
b If a patient experienced more than one other-related AE with different CTCAE grades, then the worst CTCAE grade is
counted in this table.
c If a patient experienced more than one other-related AE with the same worst CTCAE grade, then they are counted once
in the first section and once under each nature of AE.
d Multiple events per patient are counted once.
e Fisher’s exact tests were calculated to compare differences between HLA A2 groups for each type of CTCAE term.
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Primary outcome
The primary outcome was BCR–ABL response (CMR or minor or major response) observed during the trial.
There were two BCR–ABL responses, both of which were defined as a major response, one in each HLA
A2 group. Hence, there were no differences observed between the groups (Table 20).
TABLE 20 The BCR–ABL response: CMR or minor or major – molecular analysis populationa
Characteristic HLA A2+ HLA A2– Total
BCR–ABL response (CMR or minor or major), n (%)
No 11 (91.7) 7 (87.5) 18 (90.0)
Yes 1 (8.3) 1 (12.5) 2 (10.0)
Total 12 (100) 8 (100) 20 (100)
Fisher’s exact test p-valueb≥ 0.999
a Only responses measured at weeks 4, 8, 12, 16, 20, 32 and months 11, 17 and 23 were considered in the analysis,
as predefined in the protocol.
b Fisher’s exact tests were calculated to compare differences between HLA A2+ and HLA A2– by BCR–ABL response.
TABLE 19 Summary of pain relief taken following vaccination: safety analysis population – HLA A2+ patients only
Characteristic HLA A2+ (N= 12), n (%)




Types of concomitant medications taken for pain within 48 hours of vaccinationsb
Paracetamol 1 (14.3)
Paracetamol and ibuprofen 2 (28.6)
Tramadol for arthritis 4 (57.1)
Total 7 (100)
Within 48 hours of vaccination, how much relief have pain treatments or medications provided?c
Median scored
n 2




Median (IQR) 25% (10–40%)
Range 10–40%
IQR, interquartile range.
a Percentages are based on non-missing data.
b All types of medications taken because of pain within 48 hours of vaccination. Percentages are based on the total
number of concomitant medications taken.
c How much relief: range of 0% to 100%, where 0% means no relief and 100% means complete relief.
d Median score calculated for each patient across all vaccination visits.
e Worst score calculated for each patient across all vaccination visits.
TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
44
Secondary outcomes
Breakpoint cluster region–Abelson response (major or complete
molecular response)
The BCR–ABL major and CMR responses were evaluated, with no change in results to those seen in the
primary end point (Table 21).
WT1 response
There were three WT1 responses observed, all of which were defined as CMR. Two responses were
observed in the HLA A2+ group and one in the HLA A2– group. There were no differences observed
between the groups (Table 22).
Follow-up
Median follow-up time was 18 months for HLA A2+ patients and 15 months for HLA A2– patients.
No significant differences between the study arms were detected (Table 23).
A Kaplan–Meier plot for time to last follow-up in the ITT population is presented in Figure 5.
TABLE 21 The BCR–ABL response: CMR or major – molecular analysis populationa
Characteristic HLA A2+ HLA A2– Total
BCR–ABL response (CMR or minor or major), n (%)
No 11 (91.7) 7 (87.5) 18 (90.0)
Yes 1 (8.3) 1 (12.5) 2 (10.0)
Total 12 (100) 8 (100) 20 (100)
Fisher’s exact test p-valueb ≥ 0.999
a Only responses measured at weeks 4, 8, 12, 16, 20, 32 and months 11, 17 and 23 were considered in the analysis as
predefined in the protocol.
b Fisher’s exact tests were calculated to compare differences between HLA A2+ and HLA A2– by BCR–ABL response.
TABLE 22 The WT1 response: CMR or minor or major – molecular analysis populationa
Characteristic HLA A2+ HLA A2– Total
WT1 response (CMR or minor or major), n (%)
No 10 (83.3) 7 (87.5) 17 (85.0)
Yes 2 (16.7) 1 (12.5) 3 (15.0)
Total 12 (100) 8 (100) 20 (100)
Fisher’s exact test p-valueb ≥ 0.999
a Only responses measured at weeks 4, 8, 12, 16, 20, 32 and months 11, 17 and 23 were considered in the analysis as
predefined in the protocol.
b Fisher’s exact tests were calculated to compare differences between HLA A2+ and HLA A2– by BCR–ABL response.
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TABLE 23 Follow-up information: ITT population
Characteristic HLA A2+ (n= 13) HLA A2– (n= 9) Total (n= 22)
Time to last follow-up from date of consent (months)a
Median (90% CI) 18.3 (14.6 to 26.7) 15.0 (14.5 to 23.0) 18.1 (14.6 to 23.0)
Follow-up at 6 months, % (90% CI) 92.3 (66.0 to 98.5) 88.9 (54.3 to 97.8) 90.9 (73.7 to 97.1)
Follow-up at 12 months, % (90% CI) 84.6 (58.6 to 94.9) 88.9 (54.3 to 97.8) 86.4 (68.4 to 94.5)
Follow-up at 18 months, % (90% CI) 53.8 (29.4 to 73.1) 44.4 (17.8 to 68.3) 50.0 (31.7 to 65.8)
Follow-up at 24 months, % (90% CI) 30.8 (12.2 to 51.7) 22.2 (5.1 to 46.7) 27.3 (13.3 to 43.3)
Log-rank test
Number of events observed, n (%) 13 (100) 9 (100) 22 (100)
p-value 0.463
Cox’s proportional hazards model
Hazard ratio (90% CI)b 0.721 (0.343 to 1.516)
p-value 0.469
CI, confidence interval.
a Follow-up is defined as time from date of consent to date of last follow-up. Patients who die are censored at the date
of death.
b The reference category for the hazard ratio is HLA A2– patients, i.e. a hazard ratio of > 1 represents a favourable
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FIGURE 5 Kaplan–Meier for time to last follow-up: ITT population.
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Progression-free survival
There were no disease progression or deaths observed in this trial (Table 24).
A Kaplan–Meier plot for time to disease progression or death in the ITT population is presented
in Figure 6.
TABLE 24 Progression-free survival: ITT population
Characteristic HLA A2+ (n= 13) HLA A2– (n= 9) Total (n= 22)
Time to progression or death (PFS) from date of consent (months)a
Median (90% CI) NR (NR to NR) NR (NR to NR) NR (NR to NR)
PFS at 6 months, % (90% CI) 100 (NA) 100 (NA) 100 (NA)
PFS at 12 months, % (90% CI) 100 (NA) 100 (NA) 100 (NA)
PFS at 18 months, % (90% CI) 100 (NA) 100 (NA) 100 (NA)
PFS at 24 months, % (90% CI) 100 (NA) 100 (NA) 100 (NA)
Log-rank test
Number of events observed 0 0 0
p-value NA
Cox’s proportional hazards model
Hazard ratio (90% CI)b NA
p-value NA
CI, confidence interval; NA, not applicable; NR, not reached.
a Progression-free survival defined as time from date of consent to date of progression, last follow-up or death (whichever
occurs first). Patients who die and do not progress are censored at the date of death/last follow-up.
b The reference category for the hazard ratio is HLA A2– patients, i.e. a hazard ratio of > 1 represents a favourable
outcome for HLA A2– patients; and a hazard ratio of < 1 represents a favourable outcome for HLA A2+ patients.
9 8 8 5 3 2 1 0
13 13 12 9 6 4 2

























FIGURE 6 Kaplan–Meier for time to disease progression or death: ITT population.
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Overall survival
There were no deaths observed in this trial (Table 25).
A Kaplan–Meier plot for time to death in the ITT population is presented in Figure 7.
TABLE 25 Overall survival: ITT population
Characteristic HLA A2+ (n= 13) HLA A2– (n= 9) Total (n= 22)
Time to death (OS) from date of consent (months)a
Median (90% CI) NR (NR to NR) NR (NR to NR) NR (NR to NR)
OS at 6 months, % (90% CI) 100 (NA) 100 (NA) 100 (NA)
OS at 12 months, % (90% CI) 100 (NA) 100 (NA) 100 (NA)
OS at 18 months, % (90% CI) 100 (NA) 100 (NA) 100 (NA)
OS at 24 months, % (90% CI) 100 (NA) 100 (NA) 100 (NA)
Log-rank test
Number of events observed 0 0 0
p-value NA
Cox’s proportional hazards model
Hazard ratio (90% CI)b NA (NA)
p-value NA
CI, confidence interval; NA, not applicable; NR, not reached; OS, overall survival.
a OS defined as time from date of consent to date of last follow-up or death (whichever occurs first). Patients who do not
die are censored at the date of last follow-up.
b The reference category for the hazard ratio is HLA A2– patients, i.e. a hazard ratio of > 1 represents a favourable
outcome for HLA A2– patients; and a hazard ratio of < 1 represents a favourable outcome for HLA A2+ patients.
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FIGURE 7 Kaplan–Meier for time to death: ITT population.
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Time to next treatment
Time to next treatment is defined as time from date of consent to the date of next CML treatment or date
of last follow-up (whichever occurs first). No additional CML treatment was administered to any patients
within this trial (Table 26).
A Kaplan–Meier plot for time to next treatment in the ITT population is presented in Figure 8.
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FIGURE 8 Kaplan–Meier for time to next treatment: ITT population.
TABLE 26 Time to next treatment: ITT population
Characteristic HLA A2+ (n= 13) HLA A2– (n= 9) Total (n= 22)
Time to next treatment from date of consent (months)a
Median (90% CI) NR (NR to NR) NR (NR to NR) NR (NR to NR)
Time to next treatment at 6 months, % (90% CI) 100 (NA) 100 (NA) 100 (NA)
Time to next treatment at 12 months, % (90% CI) 100 (NA) 100 (NA) 100 (NA)
Time to next treatment at 18 months, % (90% CI) 100 (NA) 100 (NA) 100 (NA)
Time to next treatment at 24 months, % (90% CI) 100 (NA) 100 (NA) 100 (NA)
Log-rank test
Number of events observed 0 0 0
p-value NA
Cox’s proportional hazards model
Hazard ratio (90% CI)b NA (NA)
p-value NA
NA, not applicable; NR, not reached.
a Time to next treatment defined as time from date of consent to date of last follow up or next CML treatment (whichever
occurs first). Patients who die or do not have a next treatment are censored at the date of death/last follow-up.
b The reference category for the hazard ratio is HLA A2– patients, i.e. a hazard ratio of > 1 represents a favourable
outcome for HLA A2– patients; and a hazard ratio of < 1 represents a favourable outcome for HLA A2+ patients.
DOI: 10.3310/eme03030 EFFICACY AND MECHANISM EVALUATION 2016 VOL. 3 NO. 3
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Ottensmeier et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
49
Time to response
Two BCR–ABL responses were observed. One patient in the HLA A2+ group had a response at week 8 and
one patient in the HLA A2– group had a response at month 23. The data suggest a vaccine response in
the HLA A2+ patient and a late imatinib response in the HLA A2– patient (Table 27).
A Kaplan–Meier plot for time to for time to BCR–ABL molecular response in the molecular analysis
population is presented in Figure 9.
TABLE 27 Time to, and duration of, BCR–ABL response: major or minor or CMR – molecular analysis population
Characteristic HLA A2+ (n= 12) HLA A2– (n= 8) Total (n= 20)
Time to BCR–ABL response from beginning of inhibitor treatment (years)a
Median time (90% CI) NR (NR to NR) NR (NR to NR) NR (NR to NR)
Log-rank test
Number of events observed, n (%) 1 (8.3) 1 (12.5) 2 (10.0)
p-value 0.768 –
Cox’s proportional hazards model
Hazard ratio (90% CI)b 0.661 (0.064 to 6.782) –
p-value 0.770 –
Time to BCR–ABL response from date of informed consent (months)c
Median time (90% CI) NR (NR to NR) NR (22.8 to NR) NR (22.8 to NR)
Log-rank test
Number of events observed, n (%) 1 (8.3) 1 (12.5) 2 (10.0)
p-value 0.695 –
Cox’s proportional hazards model
Hazard ratio (90% CI)b 0.577 (0.056 to 5.947) –
p-value 0.699 –
Duration of BCR–ABL response (weeks)d
n 1e 1 2
Median (IQR) 23.1 (23.1–23.1) 4.1 (4.1–4.1) 13.6 (4.1–23.1)
Range 23.1–23.1 4.1–4.1 4.1–23.1
CI, confidence interval; IQR, interquartile range; NR, not reached.
a Time to BCR–ABL response in years is defined as time from date of beginning TKI treatment to date of last BCR–ABL
sample or the first date of BCR–ABL response (whichever occurs first). Patients who did not respond were censored at
the date of last BCR–ABL response.
b The reference category for the hazard ratio is HLA A2– patients, i.e. a hazard ratio of > 1 represents a favourable
outcome for HLA A2– patients; a hazard ratio of < 1 represents a favourable outcome for HLA A2+ patients.
c Time to BCR–ABL response in months is defined as time from date of consent to date of last BCR–ABL sample or the first
date of BCR–ABL response (whichever occurs first). Patients who did not respond were censored at the date of last
BCR–ABL response.
d Duration of BCR–ABL response is calculated by date of sample where BCR–ABL molecular response definition no longer
satisfied minus first date BCR–ABL response confirmed.
e BCR–ABL response definition was still satisfied at their last sample in the trial.
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FIGURE 9 Kaplan–Meier for time to BCR–ABL molecular response: molecular analysis population. (a) From
beginning of TKI treatment (in years); and (b) from informed consent (in months).
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There were three WT1 responses observed. HLA A2+ patients experienced responses at week 20 and
week 32. The patient in the HLA A2– group had a response at week 8 (Table 28).
A Kaplan–Meier plot for time to for time to WT1 molecular response in the molecular analysis population
is provided in Figure 10.
TABLE 28 Time to, and duration of, WT1 response: major or minor or CMR – molecular analysis population
Characteristic HLA A2+ (n= 12) HLA A2– (n= 8) Total (n= 20)
Time to WT1 response from beginning of inhibitor treatment (years)a
Median time (90% CI) NR (8.0 to NR) NR (8.7 to NR) NR (8.7 to NR)
Log-rank test
Number of events observed, n (%) 2 (16.7) 1 (12.5) 3 (15.0)
p-value 0.764
Cox’s proportional hazards model
Hazard ratio (90% CI)b 0.688 (0.088 to 5.397)
p-value 0.765
Time to WT1 response from date of informed consent (months)c
Median time (90% CI) NR (NR to NR) NR (NR to NR) NR (NR to NR)
Log-rank test
Number of events observed, n (%) 2 (16.7) 1 (12.5) 3 (15.0)
p-value 0.879
Cox’s proportional hazards model
Hazard ratio (90% CI)b 1.205 (0.161 to 9.050)
p-value 0.879
Duration of WT1 response (weeks)d
n 2 1 3
Median (IQR) 2.0 (1.7– 2.3) 5.0 (5.0–5.0) 2.3 (1.7–5.0)
Range 1.7–2.3 5.0–5.0 1.7–5.0
CI, confidence interval; IQR, interquartile range; NR, not reached.
a Time to WT1 response in years is defined as time from date of beginning TKI treatment to date of last WT1 sample or
the first date of WT1 response (whichever occurs first). Patients who did not respond were censored at the date of last
WT1 response.
b The reference category for the hazard ratio is HLA A2– patients, i.e. a hazard ratio > 1 represents a favourable outcome
for HLA A2– patients; a hazard ratio < 1 represents a favourable outcome for HLA A2+ patients.
c Time to WT1 response in months is defined as time from date of consent to date of last BCR–ABL sample or the first
date of WT1 response (whichever occurs first). Patients who did not respond were censored at the date of last
WT1 response.
d Duration of BCR–ABL response is calculated by date of sample where WT1 molecular response definition no longer
satisfied – first date WT1 response confirmed.
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FIGURE 10 Kaplan–Meier for time to WT1 molecular response: molecular analysis population. (a) From beginning
of inhibitor treatment (in years); and (b) from informed consent (in months).
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Pain assessment immediately after vaccination
Patient 2-C-021 did not receive any treatment, as outlined by the missing pain assessment data values
described in Table 29.
Pain assessment 48 hours post vaccination
Pain and discomfort data were measured on a visual analogue scale ranging from 0 (no pain/discomfort)
to 10 (worst ever pain/discomfort). Electroporation was well tolerated, with short-lived clinical effects
on the patient. No new safety information emerged on electroporation.
Patient 2-C-021 did not receive any treatment, as outlined by the missing pain assessment data values
described in Table 30.
TABLE 29 Pain assessmenta immediately after vaccination: ITT population – HLA A2+ patients only
Characteristic HLA A2+ (n= 13)
Median pain score recordedb
How severe is your pain or discomfort now?
n 12
Median (IQR) 1.0 (1.0–2.3)
Range 0.0–5.0
How severe was your pain or discomfort during and immediately after the injection?
n 12
Median (IQR) 3.0 (2.0–5.0)
Range 1.0 to 9.0
How distressing is your pain or discomfort now?
n 12
Median (IQR) 1.0 (0.3–1.0)
Range 0.0–3.0
How distressing was your pain or discomfort during and immediately after the injection?
n 12
Median (IQR) 2.3 (1.0–4.0)
Range 0.0–8.5
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TABLE 29 Pain assessmenta immediately after vaccination: ITT population – HLA A2+ patients only (continued )
Characteristic HLA A2+ (n= 13)
Worst pain score recordedc
How severe is your pain or discomfort now?
n 12
Median (IQR) 3 (1.50–5.0)
Range 1.0–6.0
How severe was your pain or discomfort during and immediately after the injection?
n 12
Median (IQR) 5.0 (3.5–7.0)
Range 1.0–9.0
How distressing is your pain or discomfort now?
n 12
Median (IQR) 2.0 (1.0–2.0)
Range 1.0–5.0
How distressing was your pain or discomfort during and immediately after the injection?
n 12
Median (IQR) 4.0 (2.0–7.0)
Range 1.0–9.0
IQR, interquartile range.
a Pain assessment scoring based on a scale of 0 to 10, where 0 represents no pain and 10 represents worst pain imaginable.
b Median score for each pain assessment question obtained by calculating the summary statistics using the median score
for the corresponding pain assessment question recorded for each patient across all vaccination visits.
c Worst pain score for each pain assessment question obtained by calculating the summary statistics using the maximum
(worst) score for the corresponding pain assessment question recorded for each patient across all vaccination visits.
TABLE 30 Pain assessmenta 48 hours post vaccination: ITT population – HLA A2+ patients only
Characteristic HLA A2+ (n= 13)
Median pain score recordedb
Pain at its worst in the last 48 hours?
n 12
Median (IQR) 0.5 (0.0–1.0)
Range 0.0–4.0
Pain at its least in the last 48 hours?
n 12
Median (IQR) 0.0 (0.0–0.0)
Range 0.0–1.0
Pain at its average in the last 48 hours?
n 12
Median (IQR) 0.3 (0.0–1.0)
Range 0.0–1.0
continued
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TABLE 30 Pain assessmenta 48 hours post vaccination: ITT population – HLA A2+ patients only (continued )
Characteristic HLA A2+ (n= 13)
How much pain do you have right now?
n 12
Median (IQR) 0.0 (0.0–0.0)
Range 0.0–1.0
During the past 48 hours, has pain interfered with your general activity?
n 12
Median (IQR) 0.0 (0.0–0.0)
Range 0.0–1.0
During the past 48 hours, has pain interfered with your mood?
n 12
Median (IQR) 0.0 (0.0–0.0)
Range 0.0–1.0
During the past 48 hours, has pain interfered with your walking ability?
n 12
Median (IQR) 0.0 (0.0–0.0)
Range 0.0–0.0
During the past 48 hours, has pain interfered with your normal work?
n 12
Median (IQR) 0.0 (0.0–0.0)
Range 0.0–1.0
During the past 48 hours, has pain interfered with your relations with other people?
n 12
Median (IQR) 0.0 (0.0–0.0)
Range 0.0–0.0
During the past 48 hours, has pain interfered with your sleep?
n 12
Median (IQR) 0.0 (0.0–0.0)
Range 0.0–2.5
During the past 48 hours, has pain interfered with your enjoyment of life?
n 12
Median (IQR) 0.0 (0.0–0.5)
Range 0.0–1.5
Worst pain score recordedc
Pain at its worst in the last 48 hours?
n 12
Median (IQR) 1.0 (1.0–2.0)
Range 0.0–8.0
Pain at its least in the last 48 hours?
n 12
Median (IQR) 0.0 (0.0–1.0)
Range 0.0–1.0
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TABLE 30 Pain assessmenta 48 hours post vaccination: ITT population – HLA A2+ patients only (continued )
Characteristic HLA A2+ (n= 13)
Pain at its average in the last 48 hours?
n 12
Median (IQR) 1.0 (0.5–1.0)
Range 0.0–4.0
How much pain do you have right now?
n 12
Median (IQR) 0.0 (0.0–0.5)
Range 0.0–1.0
During the past 48 hours, has pain interfered with your general activity?
n 12
Median (IQR) 0.0 (0.0–0.5)
Range 0.0–3.0
During the past 48 hours, has pain interfered with your mood?
n 12
Median (IQR) 0.0 (0.0–1.0)
Range 0.0–6.0
During the past 48 hours, has pain interfered with your walking ability?
n 12
Median (IQR) 0.0 (0.0–0.0)
Range 0.0–0.0
During the past 48 hours, has pain interfered with your normal work?
n 12
Median (IQR) 0.0 (0.0–0.5)
Range 0.0–2.0
During the past 48 hours, has pain interfered with your relations with other people?
n 12
Median (IQR) 0.0 (0.0–0.0)
Range 0.0–1.0
During the past 48 hours, has pain interfered with your sleep?
n 12
Median (IQR) 0.0 (0.0–0.5)
Range 0.0–4.0
During the past 48 hours, has pain interfered with your enjoyment of life?
n 12
Median (IQR) 0.0 (0.0–1.0)
Range 0.0–4.0
IQR, interquartile range.
a Pain assessment scoring based on a scale of 0 to 10, where 0 represents no pain and 10 represents worst
pain imaginable.
b Median score for each pain assessment question obtained by calculating the summary statistics using the median score
for the corresponding pain assessment question recorded for each patient across all vaccination visits.
c Worst pain score for each pain assessment question obtained by calculating the summary statistics using the maximum
(worst) score for the corresponding pain assessment question recorded for each patient across all vaccination visits.
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Immunological analysis
Immunological humoral (antibody) and cellular responses to the vaccine were assessed, using validated
assays, in blood and/or bone marrow of 10 out of 12 evaluable vaccinated patients. Results are reported
for 10 out of 12 vaccinated patients. Samples for patient 3-C-019 were lost in a freezer thaw at a site prior
to the analysis, as were baseline and multiple later time points for serum and cellular samples for patient
3-C-017. Patients 3-C-019 and 3-C-017 were therefore not immunologically evaluable. Immunological
analyses demonstrated that the p.DOM–WT1 vaccine can stimulate measurable immune responses against
both the DOM and the WT1 components in CML patients in chronic phase on imatinib.
Positive responses to the tetanus-derived component of the p.DOM–WT1 vaccine were assessed by
measuring levels of anti-FrC antibody in the patient serum by validated ELISAs. A positive response was
assigned for a post-vaccination time point with a greater than twofold increase as well as significantly
greater levels of anti-FrC antibody compared with pre-vaccination baseline (p< 0.05, Dunnett’s multiple
comparisons test). Positive FrC-antibody responses were detected in a total of 10 out of 10 (100%)
evaluable vaccinated patients, providing confirmation of successful vaccine delivery (see Appendix 3).
Immunological responses to the antigen-specific (WT1) component of the vaccine were measured using
the validated WT1 tetramer assay. A positive response was assigned when tetramer staining for a time
point was greater than twofold over baseline and confirmed by three out of three members of an
independent flow cytometry expert panel. WT1-specific T cells were detected for total of 7 out of 10
(70%) evaluable vaccinated patients (see Appendix 4). This included responses to the WT1-37 peptide in
6 out of 10 (60%) and to WT1-126 peptide in 2 out of 10 (20%) evaluable patients.
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Chapter 5 Discussion and summary of findings
The study met its primary decision-making target with one major molecular response in BCR–ABLtranscript levels. This was the decision-making point for opening the study to the full cohort as well as
the AML part of the trial (funded by Bloodwise). The early onset of the major molecular response suggests
that vaccination has achieved this molecular event. Two WT1 molecular responses were observed and
one WT1 response was seen in the HLA A2– group. One of the control patients developed a BCR–ABL
response at 23 weeks.
The vaccine and electroporation appeared safe, with no new toxicities observed or noted. The evaluation
of patients for AEs of special interest did not reveal safety concerns. One patient with pre-existing
compensated renal failure had fluctuating renal function, but no significant change from baseline was
observed. No significant cardiac toxicity or bone marrow toxicities were observed. One event of palpitation
was most likely related to anxiety pre-vaccination/pre-electroporation.
No significant differences in frequency of AEs between the HLA A2+ or HLA A2– groups were seen.
AEs related to vaccination site reaction were numerically more frequent in the HLA A2+ group; this did
not reach significance – a reflection of small sample size.
At an immunological level the vaccine performed as expected. Positive responses to the tetanus-derived
component of the p.DOM–WT1 vaccine were assessed by measuring levels of anti-FrC antibody in the
patient serum by validated ELISA. A positive response was assigned for a post-vaccination time point with
greater than twofold increase as well as significantly greater levels of anti-FrC antibody compared with
pre-vaccination baseline (p< 0.05, Dunnett’s multiple comparisons test). Positive FrC-antibody responses
were detected in a total of 10 out of 10 (100%) evaluable vaccinated patients, providing confirmation of
successful vaccine delivery.
Immunological responses to the antigen-specific (WT1) component of the vaccine were measured using
the validated WT1 tetramer assay. A positive response was assigned when tetramer staining for a time
point was greater than twofold over baseline and confirmed by three independent flow cytometry experts.
Overall, WT1-specific T cells were detected for total of 7 out of 10 (70%) evaluable vaccinated patients.
This included responses to WT1-37 peptide in 6 out of 10 (60%) and to WT1-126 peptide in 2 out of 10
(20%) evaluable patients.
The immunological analyses for the WIN trial provide evidence to show that the p.DOM–WT1 vaccine can
stimulate measurable immune responses against both the DOM and the WT1 components in chronic-phase
CML patients on imatinib.
Recruitment could not be completed for multiple reasons. The key study centre had access to only a
fraction of the predicted clinical cohort, severely limiting recruitment of CML patients. Unexpectedly, there
was no access to AML patients in this study centre. The principal clinical investigator moved out of the
country, and this resulted in loss of oversight and recruitment in the key centre. Attempts to recruit other
centres were hampered by directly competing studies and, therefore, the CML extension cohort and the
AML cohorts could not be pursued.
This is particularly disappointing as the robust induction of FrC responses (10/10 evaluable patients)
and WT1 T-cell responses in 7 out of 10 evaluable patients support that the preclinical data link to
immunological outcomes as predicted.
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The observation that only 1 out of 12 patients exhibited amolecular response suggests that the rate
of clinical benefit in patients on imatinib in chronic-phase CML is low, although if it were possible to
withdraw imatinib in 10% of patients this would be clinically significant. Although immunogenicity
supports effective delivery of the vaccine and stimulation of the expected immune response, we do
not intend to further assess the vaccine approach in this clinical context.
Evaluation in AML remains attractive clinically, but is unlikely to be feasible at this time. A combination of
the DNA vaccine approach with strategies to expand T-cell responses with immunomodulatory antibodies
is currently being developed.
DISCUSSION AND SUMMARY OF FINDINGS
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Appendix 1 Pain assessment tool: immediately
after vaccination
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Appendix 2 Pain assessment tool: 48 hours
after vaccination
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Appendix 3 Anti-fragment C from tetanus toxin
antibody enzyme-linked immunosorbent assay results
Anti-FrC antibody ELISA results are shown as mean relative antibody units at each time point(0–23 weeks). Positive responses (shown highlighted in green) represent a greater than twofold,
and significantly greater than pre-vaccination, baseline (p< 0.05, Dunnett’s multiple comparisons test).
Blue shading represents no sample. The final column shows overall response, with a maximum fold
increase relative to baseline.
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00 01 02 03 04 05 06 07 08 09 10
1-C-005 0.4215 0.4151 0.6618 0.6491 0.8572 0.8491 0.7884 0.7357 0.8395 0.8159 0.8159
1-C-022 0.0517 0.0624 0.0899 0.4052 1.1441 1.4248 1.6481 1.7005 1.7878 1.7795
1-C-023 0.6330 0.5645 1.0376 1.0156 1.2872 1.2920 1.2381 1.8903 1.6056 1.7529
2-C-002 1.5938 2.2106 4.4236 2.9914 3.6068 4.7370 3.1848 3.2868 2.8729 5.1475 4.5656
2-C-004 0.1043 0.1389 0.1340 0.0573 0.1130 0.2688 0.2195 0.2440 0.2212 0.4068 0.3736
2-C-007 0.0854 0.1092 0.1098 0.1417 0.3030 0.4984 0.6170 0.7719 0.4890 0.8262 0.7443
2-C-010 0.4321 0.5565 1.0132 1.2200 0.9896 1.4916 1.4232 1.4452 1.3271 1.3318 1.2191
2-C-012 0.6950 0.7023 1.2529 1.1530 1.1180 1.0267 1.1176 1.3059 1.6607 1.6134 1.5593
2-C-013 0.1304 0.1458 0.3887 0.3314 0.3412 0.4077 0.4102 0.4713 0.4341 0.4839




0 0 4 4 8 8 6 8 8 9 6
NA, not applicable.
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Overall
result11 12 13 14 15 16 17 18 19 20 23
0.7603 0.7135 0.5409 0.5194 0.4560 0.6307 0.5164 0.5923 2.0
1.8024 1.2027 0.9147 0.7652 34.9
1.4973 1.4630 1.3148 1.0102 0.9034 3.0
2.3297 4.5745 3.0819 3.1852 2.7010 3.3740 3.2
0.1449 0.1633 0.0702 0.0691 3.9
0.3447 9.7
0.8340 0.7065 0.6568 0.6074 0.7267 3.5
1.2250 1.8651 1.0415 2.7
0.2557 3.7
0.5880 3.9
0.4440 0.4829 0.3703 NA
3 2 3 1 0 0 0 0 0 1 1 10/11
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Appendix 4 Tetramer analysis results for
WT1-37 and WT1-126 peptides
Tetramer analysis results for WT1-37 and WT1-126 peptides are shown as percentage oftetramer-positive cells within the CD8+ T-cell population. Positive responses (shown highlighted in green)
represent a post-vaccination time point greater than twofold increase over baseline and confirmed as real by three
independent flow cytometrists. Blue shading represents no sample. The final two columns show overall response,
with a maximum fold increase relative to baseline.
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00 01 02 03 04 05 06 07 08 09 10
WT1-37
1-C-005 0.0152 0.0152 0.0210 0.0120 0.0117 0.0088 0.0120 0.0183 0.0093 0.0125 0.0135
1-C-022 0.0025 0.0013 0.0036 0.0039 0.0016 0.0024 0.0012 0.0021 0.0022 0.0004 0.0035
1-C-023 0.0074 0.0115 0.0110 0.0186 0.0243 0.0267 0.0277 0.0119 0.0276 0.0162
2-C-002 0.0378 0.0455 0.0667 0.0547 0.0844 0.0760 0.0663 0.0794 0.0775 0.0612 0.0631
2-C-004 0.0026 0.0008 0.0046 0.0034 0.0122 0.0042 0.0063 0.0023 0.0040 0.0057 0.0054
2-C-007 0.0032 0.0027 0.0074 0.0031 0.0079 0.0036 0.0038 0.0035 0.0074 0.0037 0.0020
2-C-010 0.0031 0.0016 0.0037 0.0047 0.0037 0.0037 0.0036 0.0052 0.0021 0.0031 0.0047
2-C-012 0.0028 0.0041 0.0027 0.0158 0.0274 0.0227 0.0182 0.0147 0.0256 0.0162 0.0093
2-C-013 0.0136 0.0117 0.0097 0.0175 0.0148 0.0117 0.0147 0.0132 0.0091 0.0117




0 0 2 2 5 4 2 3 5 3 0
WT1-126
1-C-005 0.0040 0.0040 0.0035 0.0055 0.0082 0.0090 0.0085 0.0085 0.0067 0.0043 0.0062
1-C-022 0.0005 0.0008 0.0016 0.0004 0.0008 0.0008 0.0013 0.0026 0.0009 0.0004 0.0018
1-C-023 0.0050 0.0055 0.0060 0.0070 0.0068 0.0064 0.0085 0.0076 0.0140 0.0112
2-C-002 0.0021 0.0028 0.0031 0.0035 0.0018 0.0028 0.0036 0.0030 0.0027 0.0022 0.0021
2-C-004 0.0007 0.0007 0.0008 0.0000 0.0032 0.0010 0.0011 0.0006 0.0017 0.0025 0.0024
2-C-007 0.0012 0.0035 0.0023 0.0040 0.0037 0.0026 0.0019 0.0013 0.0006 0.0029 0.0013
2-C-010 0.0021 0.0021 0.0000 0.0010 0.0005 0.0010 0.0031 0.0026 0.0016 0.0021 0.0032
2-C-012 0.0020 0.0015 0.0006 0.0005 0.0015 0.0015 0.0010 0.0000 0.0019 0.0017 0.0023
2-C-013 0.0015 0.0026 0.0000 0.0015 0.0015 0.0017 0.0036 0.0036 0.0035 0.0046




0 0 0 0 0 1 1 1 1 0 0
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Overall
result11 12 13 14 15 16 17 18 19 20 23
0.0160 0.0155 0.0090 0.0074 0.0075 0.0086 0.0149 0.0085
0.0017 0.0012 0.0017 0.0009 0.0015
0.0181 0.0230 0.0223 0.0225 0.0099 3.7
0.0696 0.0490 0.0483 0.0633 0.0648 0.0592 2.3
0.0051 0.0045 0.0069 0.0060 4.7
0.0024 2.3
0.0036 0.0026 0.0042 0.0030




2 2 1 2 0 0 1 0 0 0 1 6/11
0.0048 0.0065 0.0030 0.0050 0.0045 0.0050 0.0045 0.0065 2.2
0.0004 0.0009 0.0008 0.0005 0.0010
0.0120 0.0065 0.0123 0.0120 0.0097 2.8
0.0023 0.0035 0.0093 0.0102 0.0035 0.0064
0.0007 0.0020 0.0000 0.0007
0.0006





1 0 1 1 0 0 0 0 0 0 1 2/11
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